

(51) International Patent Classification:
C07D 471/08 (2006.01)(21) International Application Number:
PCT/US2015/035606(22) International Filing Date:
12 June 2015 (12.06.2015)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
62/011,696 13 June 2014 (13.06.2014) US(71) Applicant: PURDUE PHARMA L.P. [US/US]; One
Stamford Forum, 201 Tresser Boulevard, Stamford, CT
06801 (US).(72) Inventors: TAFESSE, Laykea; 8 Windward Way, Rob-
binsville, NJ 08690 (US). YOUNGMAN, Mark, A.; 110
Franklin Court, North Wales, PA 19454 (US).(74) Agent: YANG, Weiying; Purdue Pharma L.P., One Stam-
ford, 201 Tresser Boulevard, Stamford, CT 06901 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: HETEROCYCLIC MORPHINAN DERIVATIVES AND USE THEREOF

(57) Abstract: The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R¹, R², R³, R⁴, and Z are defined as set forth in the specification. In certain embodiments, the invention is also directed to compounds of Formula II-VII and the pharmaceutically acceptable salts and solvates thereof. The invention is also directed to use of compounds of Formula I to VII, and the pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the invention are especially useful for treating pain.

HETEROCYCLIC MORPHINAN DERIVATIVES AND USE THEREOF

BACKGROUND OF THE INVENTION

Field of the Invention

This application is in the field of medicinal chemistry. The application relates to novel morphinan analogs, pharmaceutical compositions comprising one or more of these compounds, and their use.

5 Description of the Related Art

Pain is the most common symptom for which patients seek medical advice and treatment. While acute pain is usually self-limited, chronic pain can persist for 3 months or longer and lead to significant changes in a patient's personality, lifestyle, functional ability and overall quality of life (K.M. Foley, Pain, in *Cecil Textbook of Medicine* 100-107, J.C. Bennett and F. Plum eds., 20th ed. 1996).

Pain has traditionally been managed by administering either a non-opioid analgesic (such as acetylsalicylic acid, choline magnesium trisalicylate, acetaminophen, ibuprofen, fenopufen, diflunisal or naproxen), or an opioid analgesic (such as morphine, hydromorphone, methadone, levorphanol, fentanyl, oxycodone, oxymorphone, or buprenorphine).

Until recently, there was evidence of three major classes of opioid receptors in the central nervous system (CNS), with each class having subtype receptors. These receptor classes are known as μ , δ and κ . As opiates have a high affinity to these receptors while not being endogenous to the body, research followed in order to identify and isolate the endogenous ligands to these receptors. These ligands were identified as endorphins, enkephalins, and dynorphins, respectively. Additional experimentation has led to the identification of the opioid receptor-like (ORL-1) receptor, which has a high degree of homology to the known opioid receptor classes. This more recently discovered receptor was classified as an opioid receptor based only on structural grounds, as the receptor did not exhibit pharmacological homology. It was initially demonstrated that non-selective ligands having a high affinity for μ , δ and κ receptors had low affinity for the ORL-1 receptor. This characteristic, along with the fact that an endogenous ligand had not yet been discovered, led to the ORL-1 receptor being designated as an "orphan receptor".

Kappa (κ) opioid receptor agonists have been evaluated as alternatives to existing analgesics for the treatment of pain. Centrally penetrating κ agonists produce antinociceptive effects in conventional preclinical assays of basal, inflammatory and neuropathic pain (Vanderah *et al.*, *J. Pharmacol. Exp. Ther.* 310:326-333 (2004); Negus *et al.*,
5 *Psychopharmacology (Berl)* 210:149-159 (2010)). However, centrally penetrating κ agonists can also produce undesirable side-effects, such as sedative and psychotomimetic effects (Pande *et al.*, *Clin. Neuropharmacol.* 19:92-97 (1996); Pande *et al.*, *Clin. Neuropharmacol.* 19:451-456 (1996); and Wadenberg, *CNS Drug Rev.* 9:187-198 (2003)).

Opioid receptor agonists that do not readily cross the blood-brain barrier are
10 peripherally restricted and distribute poorly to the central nervous system after systemic administration. Such compounds would retain an ability to produce analgesia by acting on peripheral opioid receptors, such as peripheral κ -opioid receptors, but their potency to produce centrally mediated side-effects would be reduced.

There is a need for effective analgesics that work by acting on opioid receptors.
15 There is also a need for analgesics that work by acting on peripheral opioid receptors. There is also a need for analgesics that work by acting on central opioid receptors. There is also a need for analgesics that work by acting on κ -opioid receptors. There is also a need for analgesics that work by acting on peripheral κ -opioid receptors.

BRIEF SUMMARY OF THE INVENTION

20 In one aspect, the present disclosure provides compounds represented by Formulae I-VII, below, and the pharmaceutically acceptable salts and solvates thereof, collectively referred to herein as "Compounds of the Invention" (each is individually referred to hereinafter as a "Compound of the Invention").

In another aspect, the present disclosure provides the use of Compounds of the
25 Invention as synthesis intermediates.

In another aspect, the present disclosure provides the use of Compounds of the Invention as modulators of one or more opioid receptors. Specifically, the present disclosure provides the use of Compounds of the Invention as modulators of μ , δ , κ , and/or ORL-1 opioid receptors, and especially modulators of μ and/or κ opioid receptors.

In another aspect, the present disclosure provides a method of treating or preventing a disorder responsive to the modulation of one or more opioid receptors in a patient, comprising administering to the patient an effective amount of a Compound of the Invention. In another aspect, the present disclosure provides a use of a Compound of the Invention as an analgesic to treat or prevent pain; or as an agent to treat or prevent withdrawal from alcohol or drug addiction; or as an agent to treat or prevent addictive disorders; or as an agent to treat a pruritic condition; or as an agent to treat or prevent constipation; or as an agent to treat or prevent diarrhea (each of pain, alcohol withdrawal, drug withdrawal, addictive disorders, pruritis, constipation, and diarrhea being a "Condition").

The present invention further provides methods of treating or preventing a Condition, comprising administering to a patient in need thereof a therapeutically effective amount of a Compound of the Invention. In certain embodiments, the Condition is pain (including acute pain, chronic pain (which includes but is not limited to, neuropathic pain, postoperative pain, and inflammatory pain), and surgical pain). The Compounds of the Invention are particularly useful for treating or preventing chronic pain.

In another aspect, the present disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of a Compound of the Invention and one or more pharmaceutically acceptable carriers. Such compositions are useful for treating or preventing a Condition in a patient.

In another aspect, the present disclosure provides Compounds of the Invention for use in treatment or prevention of a disorder responsive to the modulation of one or more opioid receptors. Preferably, the disorder is responsive to modulation of the μ -opioid receptor or the κ -opioid receptor, or to modulation of both the μ -opioid receptor and the κ -opioid receptor.

In another aspect, the present disclosure provides a method of modulating one or more opioid receptors in a patient in need of said modulation, comprising administering to the patient an opioid receptor modulating amount of a Compound of the Invention.

In another aspect, the present disclosure provides Compounds of the Invention for use in treatment or prevention of one or more Conditions in a patient in need of said treatment or prevention.

In another aspect, the present disclosure provides Compounds of the Invention for use in treatment or prevention of pain in a patient, such as acute pain, chronic pain (which includes but is not limited to, neuropathic pain, postoperative pain, and inflammatory pain), or surgical pain.

In another aspect, the present disclosure provides Compounds of the Invention for use in modulation of one or more opioid receptors in a patient.

In another aspect, the present disclosure provides use of Compounds of the Invention in the manufacture of a medicament for treating or preventing a disorder responsive to the modulation of one or more opioid receptors.

In another aspect, the present disclosure provides use of Compounds of the Invention in the manufacture of a medicament for modulating of one or more opioid receptors in a patient. Preferably, the μ - or κ -opioid receptor is modulated, or both the μ - and κ -opioid receptors are modulated.

In another aspect, the present disclosure provides Compounds of the Invention for use as a medicament.

In another aspect, the present disclosure provides use of a Compound of the Invention in the manufacture of a medicament for treating or preventing a Condition in a patient.

In another aspect, the present disclosure provides use of a Compound of the Invention in the manufacture of a medicament for treating or preventing pain in a patient, such as acute pain, chronic pain, or surgical pain.

In another aspect, the present disclosure provides a pharmaceutical composition, comprising a Compound of the Invention for treating or preventing a disorder responsive to the modulation of one or more opioid receptors.

The present invention further provides methods for preparing a pharmaceutical composition, comprising admixing a Compound of the Invention and a pharmaceutically acceptable carrier to form the pharmaceutical composition.

In another aspect, the present invention provides radiolabeled Compounds of the Invention, especially ^1H , ^{11}C and ^{14}C radiolabeled Compounds of the Invention, and the use of such compounds as radioligands to detect binding to an opioid receptor in screening assays.

In another aspect, the present invention provides a method for screening a candidate compound for the ability to bind to an opioid receptor, comprising a) introducing a fixed concentration of a radiolabeled Compound of the Invention to the receptor under conditions that permit binding of the radiolabeled compound to the receptor to form a complex; b) titrating the complex with a candidate compound; and c) determining the binding of the candidate compound to said receptor.

In a further aspect, the invention relates to a kit, comprising a sterile container containing an effective amount of a Compound of the Invention and instructions for therapeutic use.

In a further aspect, the present invention provides a method of making Compounds of the Invention.

Additional embodiments and advantages of the disclosure will be set forth, in part, in the description that follows, and will flow from the description, or can be learned by practice of the disclosure. The embodiments and advantages of the disclosure will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.


It is to be understood that both the foregoing summary and the following detailed description are exemplary and explanatory only, and are not restrictive of the invention as claimed.

DETAILED DESCRIPTION OF THE INVENTION

Certain Compounds of the Invention are useful for modulating a pharmacodynamic response from one or more opioid receptors (μ , δ , κ , ORL-1) either centrally or peripherally, or both. The pharmacodynamic response may be attributed to the compound either stimulating (agonizing) or inhibiting (antagonizing) the one or more receptors. Certain Compounds of the Invention may antagonize one opioid receptor, while also agonizing one or more other receptors. Compounds of the Invention having agonist activity may be either full or partial agonists.

One aspect of the invention is based on the use of certain Compounds of the Invention as synthesis intermediates.

In one embodiment, Compounds of the Invention are compounds represented by Formula I:



and pharmaceutically acceptable salts and solvates thereof, wherein:

R^1 is hydroxyl, cyano, carboxy, aminocarbonyl, alkyl, or alkoxy, wherein each of said carboxy, aminocarbonyl, alkyl, and alkoxy is optionally substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxy, halo, haloalkyl, amino, alkylamino, dialkylamino, carboxy, alkoxy, alkoxycarbonyl, aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl, wherein said aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl are optionally substituted with 1, 2, or 3 independently selected R^8 groups;

R^2 is selected from the group consisting of hydrogen, alkyl, and alkoxycarbonyl, wherein said alkoxycarbonyl is optionally substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxy, alkyl, halo, haloalkyl, amino, alkylamino, dialkylamino, carboxy, alkoxy, alkoxycarbonyl, aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl, wherein said aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl are optionally substituted with 1, 2, or 3 independently selected R^8 groups;

R^3 is hydrogen, hydroxy, or halo; or alkoxy, alkylamino, or dialkylamino, any of which is optionally substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxy, halo, haloalkyl, amino, alkylamino, dialkylamino, carboxy, alkoxy, alkoxycarbonyl, aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl, wherein said aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl are optionally substituted with 1, 2, or 3 independently selected R^8 groups;

R^4 is hydrogen or alkyl;

Z is $-C(=O)R^5$ or hydrogen, wherein

R^5 is selected from the group consisting of

(a) OH;

(b) optionally substituted alkoxy; and


(c) $-NR^6R^7$; wherein

R^6 is hydrogen or alkyl;


R^7 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and arylalkyl, wherein two adjacent carbon atoms of said cycloalkyl ring are optionally fused to a phenyl ring; and wherein each of said alkyl, cycloalkyl, and arylalkyl is optionally substituted with 1, 2, or 3 independently selected R^8 groups; or R^6 and R^7 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring; and

Each R⁸ is independently selected from the group consisting of hydroxy, halo, alkyl, haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, carboxy, alkoxy, and alkoxy carbonyl;

Provided that the compound is not any of




10 In another embodiment, Compounds of the Invention are compounds represented by Formula II:




and the pharmaceutically acceptable salts and solvates thereof, wherein R¹, R², R³, R⁴, and Z are as defined for Formula I.

In another embodiment, Compounds of the Invention are compounds represented by Formula **III**:




and the pharmaceutically acceptable salts and solvates thereof, wherein R^1 , R^2 , R^3 , R^4 and Z are as defined for Formula **I**.

In another embodiment, Compounds of the Invention are compounds represented by Formula **IV**:



and the pharmaceutically acceptable salts and solvates thereof, wherein R^1 , R^2 , R^3 , R^4 and Z are as defined for Formula **I**.

In another embodiment, Compounds of the Invention are compounds represented by Formula **V**:



and the pharmaceutically acceptable salts and solvates thereof, wherein R^1 , R^2 , R^3 , R^4 and Z are as defined for Formula **I**.

In another embodiment, Compounds of the Invention are compounds represented by any one of Formula **I**, **II**, **III**, **IV**, and **V** (referred to collectively as "Formulae **I-V**"), wherein R^1 is hydroxyl.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^1 is alkoxy, which is optionally substituted with 1, 2, or 3

substituents, each independently selected from the group consisting of hydroxy, halo, haloalkyl, amino, alkylamino, dialkylamino, carboxy, alkoxy, alkoxycarbonyl, aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl, wherein said aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl are optionally substituted with 1, 2, or 3
5 independently selected R⁸ groups.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae I-V, wherein R¹ is C₁₋₆ alkoxy, which is optionally substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxy, halo, halo(C₁₋₆)alkyl, amino, C₁₋₆ alkylamino, di(C₁₋₆)alkylamino, carboxy, C₁₋₆ alkoxy, C₁₋₆
10 alkoxycarbonyl, C₆₋₁₀ aryl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocyclo, C₃₋₇ cycloalkyl, and C₃₋₇ cycloalkenyl, wherein said aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl are optionally substituted with 1, 2, or 3 independently selected R⁸ groups. Useful R⁸ groups include hydroxy, halo, C₁₋₆ alkyl, halo(C₁₋₆)alkyl, cyano, nitro, amino, C₁₋₆ alkylamino, di(C₁₋₆)alkylamino, carboxy, C₁₋₆ alkoxy, and C₁₋₆ alkoxycarbonyl, and
15 preferably hydroxy, halo, C₁₋₄ alkyl, halo(C₁₋₄)alkyl, cyano, nitro, amino, C₁₋₄ alkylamino, di(C₁₋₄)alkylamino, carboxy, C₁₋₄ alkoxy, and C₁₋₄ alkoxycarbonyl.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae I-V, wherein R¹ is C₁₋₆ alkoxy, which is optionally substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxy, halo, halo(C₁₋₄)alkyl, amino, C₁₋₄ alkylamino, di(C₁₋₄)alkylamino, carboxy, C₁₋₄ alkoxy, and C₁₋₄
20 alkoxycarbonyl.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae I-V, wherein R¹ is unsubstituted C₁₋₆ alkoxy.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae I-V, wherein R¹ is unsubstituted methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, iso-butoxy, or sec-butoxy, and preferably R¹ is unsubstituted methoxy.
25

In another embodiment, Compounds of the Invention are compounds of any one of Formulae I-V, wherein R² is hydrogen.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae I-V, wherein R² is alkyl, and preferably C₁₋₆ alkyl. In another embodiment, R² is C₁₋₄ alkyl, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl, iso-butyl, and sec-butyl. In another embodiment, R² is methyl.
30

In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^2 is alkoxycarbonyl, wherein said alkoxycarbonyl is optionally substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxy, halo, haloalkyl, amino, alkylamino, dialkylamino, carboxy, alkoxy, 5 alkoxycarbonyl, aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl, wherein said aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl are optionally substituted with 1, 2, or 3 independently selected R^8 groups.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^2 is C_{1-6} alkoxycarbonyl, wherein said C_{1-6} alkoxycarbonyl is 10 optionally substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxy, halo, halo(C_{1-6})alkyl, amino, C_{1-6} alkylamino, di(C_{1-6})alkylamino, carboxy, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, C_{6-10} aryl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocyclo, C_{3-7} cycloalkyl, and C_{3-7} cycloalkenyl, wherein said aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl are optionally substituted with 1, 2, or 3 15 independently selected R^8 groups. Useful R^8 groups are those described above in connection with R^1 . In one embodiment, R^2 is unsubstituted C_{1-6} alkoxycarbonyl.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^2 is C_{1-4} alkoxycarbonyl, wherein said C_{1-4} alkoxycarbonyl is optionally substituted with 1, 2, or 3 substituents, each independently selected from the group 20 consisting of hydroxy, halo, halo(C_{1-4})alkyl, amino, C_{1-4} alkylamino, di(C_{1-4})alkylamino, carboxy, C_{1-4} alkoxy, and C_{1-4} alkoxycarbonyl, and preferably optionally substituted with 1 or 2 substituents, each independently selected from the group consisting of hydroxy, halo, trifluoromethyl, amino, methylamino, ethylamino, dimethylamino, diethylamino, carboxy, methoxy, ethoxy, methoxycarbonyl, and ethoxycarbonyl.

25 In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^3 is hydrogen.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^3 is hydroxy.

In another embodiment, Compounds of the Invention are compounds of any one of 30 Formulae **I-V**, wherein R^4 is hydrogen.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^4 is alkyl, preferably C_{1-6} alkyl, and more preferably C_{1-4} alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, or tert-butyl.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein Z is $-C(=O)R^5$.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^5 is OH.

5 In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^5 is optionally substituted alkoxy. In this aspect of the invention, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^5 is unsubstituted C_{1-6} alkoxy. In another embodiment, R^5 is C_{1-6} alkoxy substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxy, halo, 10 haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, carboxy, alkoxy, and alkoxycarbonyl. In another embodiment, R^5 is unsubstituted C_{1-4} alkoxy, such as methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, or tert-butoxy, or C_{1-4} alkoxy substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxy, halo, halo(C_{1-4})alkyl, cyano, nitro, amino, C_{1-4} alkylamino, di(C_{1-4})alkylamino, carboxy, C_{1-4} 15 alkoxy, and C_{1-4} alkoxycarbonyl. In one embodiment, R^5 is methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, or tert-butoxy.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^5 is $-NR^6R^7$, wherein R^6 is hydrogen or alkyl; and R^7 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and arylalkyl, wherein two adjacent 20 carbon atoms of said cycloalkyl ring are optionally fused to a phenyl ring; wherein each of said alkyl, cycloalkyl, and arylalkyl is optionally substituted with 1, 2, or 3 independently selected R^8 groups.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^5 is $-NR^6R^7$, wherein R^6 is hydrogen and R^7 is as defined in 25 connection with Formula **I**.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^5 is $-NR^6R^7$, wherein R^6 is alkyl, and preferably C_{1-6} alkyl (such as, for example, methyl, ethyl, propyl, butyl, or 3-methylbutyl) and R^7 is as defined in connection with Formula **I**.


30 In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^5 is $-NR^6R^7$, wherein R^6 is hydrogen or alkyl, and preferably C_{1-6} alkyl, and R^7 is hydrogen.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^5 is $-NR^6R^7$, wherein R^6 and R^7 are both hydrogen.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^5 is $-NR^6R^7$, wherein R^6 is hydrogen or alkyl, and R^7 is selected from the group consisting of cycloalkyl and arylalkyl, wherein two adjacent carbon atoms of said cycloalkyl are optionally fused to a phenyl ring; and wherein each of said cycloalkyl and arylalkyl are optionally substituted with 1, 2, or 3 independently selected R^8 groups. In one embodiment, R^7 is selected from the group consisting of C_{3-7} cycloalkyl and C_{6-14} aryl(C_{1-6})alkyl, wherein two adjacent carbon atoms of said C_{3-7} cycloalkyl ring are optionally fused to a phenyl ring; and wherein each of said C_{3-7} cycloalkyl and C_{6-14} aryl(C_{1-6})alkyl is optionally substituted with 1, 2, or 3 independently selected R^8 groups. In another embodiment, R^7 is selected from the group consisting of C_{3-6} cycloalkyl and C_{6-10} aryl(C_{1-4})alkyl, wherein two adjacent carbon atoms of said C_{3-6} cycloalkyl ring are optionally fused to a phenyl ring; and wherein each of said C_{3-6} cycloalkyl and C_{6-10} aryl(C_{1-4})alkyl is optionally substituted with 1, 2, or 3 independently selected R^8 groups. In another embodiment, R^7 is C_{3-6} cycloalkyl fused to a phenyl ring, such as 2,3-dihydro-1H-inden-1-yl. Suitable R^8 groups are those described in connection with R^1 .


In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein R^5 is $-NR^6R^7$, wherein R^6 is hydrogen or alkyl, and R^7 is selected from the group consisting of cyclohexyl, benzyl, phenethyl, and 2,3-dihydro-1H-inden-1-yl, any of which is optionally substituted with 1, 2, or 3 independently selected R^8 groups.

In another embodiment, Z is selected from the group consisting of




wherein R^8 is as defined above in connection with Formula **I**.

In another embodiment, Compounds of the Invention are compounds of any one of Formulae **I-V**, wherein Z is selected from the group consisting of




In another embodiment, Compounds of the Invention are compounds of any one of Formulae I-V, wherein R^5 is $-NR^6R^7$ and R^6 and R^7 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring. In another embodiment, the optionally substituted heterocyclic ring is an optionally substituted 5- or 6-membered heterocyclic ring. In this aspect of the invention, useful heterocyclic rings include unsubstituted or substituted 5- or 6-membered heterocyclic rings containing 1-2 nitrogen atoms and optionally 1 or 2 other heteroatoms. In one embodiment, the heterocyclic ring is a substituted or unsubstituted 5-membered heterocyclic ring containing 1 nitrogen atom, such as substituted or unsubstituted pyrrolidin-1-yl. In another embodiment, the heterocyclic ring is a substituted or unsubstituted 6-membered heterocyclic ring containing 1 nitrogen atom and 1 heteroatom selected from the group consisting of oxygen or sulphur, such as, for example, a substituted or unsubstituted morpholinyl, thiomorpholinyl, and dioxidothiomorpholinyl. In another embodiment, the optionally substituted heterocyclic ring is an optionally substituted bicyclic ring system. In this aspect, suitable heterocyclic rings include unsubstituted or substituted 7-10 membered bicyclic ring systems containing 1-2 nitrogen atoms and optionally 1 or 2 other heteroatoms, such as, for example, isoindolin-2-yl and azabicyclo[3.2.1]octan-8-yl. Suitable optional substituents include hydroxy, halo, C_{1-4} alkyl, halo(C_{1-4})alkyl, cyano, nitro, amino, aminocarbonyl, (C_{1-4} alkylamino)carbonyl, C_{1-4} alkylamino, di(C_{1-4})alkylamino, carboxy, C_{1-4} alkoxy, and C_{1-4} alkoxy carbonyl.

In another embodiment, R^6 and R^7 together with the nitrogen atom to which they are attached form




wherein R^9 is hydrogen, C_{1-4} alkyl, aminocarbonyl or (C_{1-4} alkylamino)carbonyl. In one embodiment, R^9 is hydrogen.

In another embodiment, R^6 and R^7 together with the nitrogen atom to which they are attached form



wherein R^8 is as defined above in connection with Formula I.

- 5 In another embodiment, Compounds of the Invention are compounds of any one of Formulae I-V, wherein Z is selected from the group consisting of



- 10 In another embodiment, Compounds of the Invention are compounds of any one of Formulae I-V, wherein


R^1 is hydroxy or unsubstituted C_{1-6} alkoxy;

- R^2 is C_{1-4} alkyl or C_{1-6} alkoxy carbonyl, wherein said C_{1-6} alkoxy carbonyl is optionally substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxy, halo, halo(C_{1-4})alkyl, amino, C_{1-4} alkylamino, di(C_{1-4})alkylamino, carboxy, C_{1-4} alkoxy, and C_{1-4} alkoxy carbonyl;
- 15


R^3 is hydrogen or hydroxy; and

R^4 is hydrogen or C_{1-4} alkyl.

- 20 In another embodiment, Compounds of the Invention are compounds of Formula I, wherein R^2 is methyl and R^4 is hydrogen, represented by Formula VI:




and the pharmaceutically acceptable salts and solvates thereof, wherein R^{10} is H or C_{1-6} alkyl optionally substituted with 1 or 2 substituents, each independently selected from the group consisting of hydroxy, halo, halo(C_{1-4})alkyl, amino, C_{1-4} alkylamino, di(C_{1-4})alkylamino, carboxy, C_{1-4} alkoxy, and C_{1-4} alkoxycarbonyl, and R^3 is hydrogen or OH, and Z^1 is selected from the group consisting of




wherein R^8 is as defined for Formula I.


In another embodiment, Compounds of the Invention are compounds of any one of Formulae I-V, wherein Z is hydrogen. In one embodiment of this aspect of the invention, R^1 is OH or unsubstituted C_{1-6} alkoxy; R^2 is C_{1-4} alkyl; R^3 is hydrogen or hydroxy; and R^4 is C_{1-4} alkyl. In another embodiment, R^1 is OH, methoxy, or ethoxy; R^2 is methyl; R^3 is hydroxy; and R^4 is methyl or ethyl.

In another embodiment, Compounds of the Invention include:






5 In another embodiment, Compounds of the Invention include:



In another embodiment, Compounds of the Invention are compounds of any one of Formulae I-V, wherein R^1 is $-O-PG$, wherein PG is a hydroxyl protecting group.

10 In another embodiment, Compounds of the Invention are compounds of Formula I, represented by Formula VII:



wherein suitable and preferable definitions for R^2 , R^3 and Z are those described above for any of Formulae I-V;

Suitable hydroxyl protecting groups for PG are well known and include, for example, any suitable hydroxyl protecting group disclosed in Wuts, P. G. M. & Greene, T. W., *Greene's Protective Groups in Organic Synthesis*, 4rd Ed., pp. 16-430 (J. Wiley & Sons, 2007), herein incorporated by reference in its entirety.

5 The term "hydroxyl protecting group" as used herein refers to a group that blocks (i.e., protects) the hydroxy functionality while reactions are carried out on other functional groups or parts of the molecule. Those skilled in the art will be familiar with the selection, attachment, and cleavage of protecting groups and will appreciate that many different protective groups are known in the art, the suitability of one protective group or another being
10 dependent on the particular synthetic scheme planned. Suitable hydroxy protecting groups are generally able to be selectively introduced and removed using mild reaction conditions that do not interfere with other portions of the subject compounds. These protecting groups can be introduced or removed at a convenient stage using methods known in the art. The chemical properties of such groups, methods for their introduction and removal are known in
15 the art and can be found, for example, in Greene, T.W. and Wuts, P.G.M., above. Additional hydroxyl protecting groups can be found, for example, in U.S. Patent No. 5,952,495, U.S. Patent Appl. Pub. No. 2008/0312411, WO 2006/035195, and WO 98/02033, which are herein incorporated in their entireties. Suitable hydroxyl protecting groups include the methoxymethyl, tetrahydropyranyl, tert-butyl, allyl, tert-butyldimethylsilyl, tert-
20 butyldiphenylsilyl, acetyl, pivaloyl, benzoyl, benzyl (Bn), and p-methoxybenzyl group.

It will be apparent to a person of ordinary skill in the art in view of this disclosure that certain groups included in the definitions of -O-PG overlap with the other definitions for R¹, such as methoxy, tert-butoxy, etc., and, thus, certain Compounds of the Invention having R¹ groups that include groups acting as hydroxyl protecting groups can be pharmaceutically
25 active as described herein.


In one embodiment, the hydroxyl protecting group PG is selected from the group consisting of alkyl, arylalkyl, heterocyclo, (heterocyclo)alkyl, acyl, silyl, and carbonate, any of which are optionally substituted.

In another embodiment, the hydroxyl protecting group PG is an alkyl group, typically
30 an optionally substituted C₁₋₆ alkyl group, and suitably unsubstituted methyl or tert-butyl. In another embodiment, the hydroxyl protecting group PG is an arylalkyl group. Suitable arylalkyl groups include, for example, an unsubstituted benzyl group, substituted benzyl groups, such as p-methoxybenzyl, and naphthylmethyl.

In another embodiment, the hydroxyl protecting group PG is a heterocyclo group, such as unsubstituted tetrahydropyranyl or optionally substituted tetrahydropyranyl.


In another embodiment, the hydroxyl protecting group PG is a (heterocyclo)alkyl group. Suitable (heterocyclo)alkyl groups include, for example, 4-morpholinyl(C₁₋₄)alkyl groups, such as, 2-(4-morpholinyl)ethyl.

In another embodiment, the hydroxyl protecting group PG is a silyl group. The term "silyl" as employed herein refers to the group having the following structure:



, wherein R¹¹, R¹², and R¹³ are each independently selected from the group consisting of alkyl, cycloalkyl, aryl, (cycloalkyl)alkyl, or arylalkyl, any of which is optionally substituted. In one embodiment, the silyl group is trimethyl silyl, tert-butyldimethyl silyl, tert-butyldiphenyl silyl, or tri-isopropyl silyl.


In another embodiment, the hydroxyl protecting group PG is an acyl group. The term "acyl" as employed herein refers to the following structure:



, wherein R¹⁴ is alkyl, cycloalkyl, aryl, (cycloalkyl)alkyl, or arylalkyl, any of which is optionally substituted. The acyl group can be, for example, C₁₋₄ alkylcarbonyl (such as, for example, acetyl), arylcarbonyl (such as, for example, benzoyl), levulinoyl, or pivaloyl.

In another embodiment, the acyl group is benzoyl.

In another embodiment, the hydroxyl protecting group is a carbonate group. The term "carbonate" as employed herein refers to the following structure:



, wherein R¹⁵ is alkyl, alkenyl, cycloalkyl, aryl, (cycloalkyl)alkyl, or arylalkyl, any of which is optionally substituted. Typically, R¹⁵ is C₁₋₁₀ alkyl (e.g., 2,4-dimethylpent-3-yl), C₂₋₆ alkenyl (e.g., ethenyl or prop-2-enyl, i.e., allyl), C₃₋₁₂ cycloalkyl (e.g., adamantyl), phenyl, or benzyl. In one embodiment, the carbonate is (benzyloxy)carbonyl.

Optional substituents attached to aryl, phenyl and heteroaryl rings each take the place of a hydrogen atom that would otherwise be present in any position on the aryl, phenyl or heteroaryl rings.

Useful halo or halogen groups include fluorine, chlorine, bromine and iodine.

Useful alkyl groups are selected from straight-chain and branched-chain C₁₋₁₀ alkyl groups. Typical C₁₋₁₀ alkyl groups include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, and n-decyl, isopropyl, *sec*-butyl, *tert*-butyl, *iso*-butyl, *iso*-pentyl, neopentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-methylhexyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 1,2-dimethylpentyl, 1,3-dimethylpentyl, 1,2-dimethylhexyl, 1,3-dimethylhexyl, 3,3-dimethylhexyl, 1,2-dimethylheptyl, 1,3-dimethylheptyl, and 3,3-dimethylheptyl, among others. In one embodiment, useful alkyl groups are selected from straight chain C₁₋₆ alkyl groups and branched chain C₃₋₆ alkyl groups. Typical C₁₋₆ alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *sec*-butyl, *tert*-butyl, *iso*-butyl, pentyl, 3-pentyl, hexyl, among others. In one embodiment, useful alkyl groups are selected from straight chain C₂₋₆ alkyl groups and branched chain C₃₋₆ alkyl groups. Typical C₂₋₆ alkyl groups include ethyl, propyl, isopropyl, butyl, *sec*-butyl, *tert*-butyl, *iso*-butyl, pentyl, 3-pentyl, hexyl among others. In one embodiment, useful alkyl groups are selected from straight chain C₁₋₄ alkyl groups and branched chain C₃₋₄ alkyl groups. Typical C₁₋₄ alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *sec*-butyl, *tert*-butyl, and *iso*-butyl.

Useful alkenyl groups are selected from straight-chain and branched-chain C₂₋₆ alkenyl groups, preferably C₂₋₄ alkenyl. Typical C₂₋₆ alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, *sec*-butenyl, pentenyl, and hexenyl. Typical C₂₋₄ alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, and *sec*-butenyl.

Useful alkynyl groups are selected from straight-chain and branched-chain C₂₋₆ alkynyl groups, preferably C₂₋₄ alkynyl. Typical C₂₋₆ alkynyl groups include ethynyl, propynyl, butynyl, 2-butyne, pentynyl, and hexynyl groups. Typical C₂₋₄ alkynyl groups include ethynyl, propynyl, butynyl, and 2-butyne groups.

Useful haloalkyl groups include any of the above-mentioned C₁₋₁₀ alkyl groups, and preferably C₁₋₆ alkyl groups, and preferably any of the above-mentioned C₁₋₄ alkyl groups, substituted by one or more fluorine, chlorine, bromine or iodine atoms (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and trichloromethyl groups).

Useful hydroxyalkyl groups include any of the above-mentioned C₁₋₁₀ alkyl groups, preferably any of the above-mentioned C₁₋₆ alkyl groups, and more preferably any of the above-mentioned C₁₋₄ alkyl groups, substituted by one or more hydroxy groups, such as monohydroxyalkyl and dihydroxyalkyl groups (e.g., hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, and hydroxyhexyl groups, and especially hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 2-hydroxypropyl, 2-hydroxyprop-2-yl, 3-hydroxypropyl, 2,3-dihydroxypropyl, 3-hydroxybutyl, 4-hydroxybutyl, 2-hydroxy-1-methylpropyl, and 1,3-dihydroxyprop-2-yl). In one embodiment, the monohydroxyalkyl is monohydroxy(C₁₋₄)alkyl. In one embodiment, the dihydroxyalkyl is dihydroxy(C₁₋₄)alkyl.

Useful cycloalkyl groups are selected from saturated cyclic hydrocarbon groups containing 1, 2, or 3 rings having 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 carbon atoms (*i.e.*, C₃-C₁₂ cycloalkyl) or the number of carbons designated. In one embodiment, the cycloalkyl has one or two rings. In another embodiment, the cycloalkyl is a C₃-C₈ cycloalkyl. In another embodiment, the cycloalkyl is a C₃₋₇ cycloalkyl. In another embodiment, the cycloalkyl is a C₃₋₆ cycloalkyl. Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, and adamantyl.

Useful cycloalkenyl groups are selected from partially unsaturated (*i.e.*, containing one or two double bonds) cyclic hydrocarbon groups containing 1, 2, or 3 rings having 4, 5, 6, 7, 8, 9, 10, 11, or 12 carbon atoms (*i.e.*, C₄-C₁₂ cycloalkenyl) or the number of carbons designated. In one embodiment, the cycloalkenyl has one or two rings. In another embodiment, the cycloalkenyl is a C₃-C₈ cycloalkenyl. In another embodiment, the cycloalkenyl is a C₃-C₇ cycloalkenyl. In another embodiment, the cycloalkenyl is a C₃-C₆ cycloalkenyl. In one embodiment, the cycloalkenyl group contains one double bond. Exemplary cycloalkenyl groups containing one double bond include cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, and cyclodecenyl. In another embodiment, the cycloalkenyl group contains two double bonds. Preferably, the cycloalkenyl groups containing two double bonds have 5, 6, 7, 8, 9, 10, 11, or 12 carbon atoms (*i.e.*, C₅-C₁₂ cycloalkadienyl). Exemplary cycloalkenyl groups having two double bonds include cyclopentadienyl, cyclohexadienyl, cycloheptadienyl, cyclooctadienyl, cyclononadienyl, and cyclodecadienyl.

Useful alkoxy groups include oxygen substituted by one of the C₁₋₁₀ alkyl groups mentioned above (e.g., methoxy, ethoxy, propoxy, iso-propoxy, butoxy, tert-butoxy, iso-

butoxy, sec-butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, nonyloxy and decyloxy), preferably by one of the C₁₋₆ alkyl groups, and more preferably one of the C₁₋₄ alkyl groups.

Useful alkoxyalkyl groups include any of the above-mentioned C₁₋₁₀ alkyl groups, and preferably any of the above-mentioned C₁₋₆ alkyl groups, substituted with any of the above-mentioned alkoxy groups (e.g., methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl, 2-ethoxyethyl, 3-ethoxypropyl, 4-ethoxybutyl, propoxymethyl, iso-propoxymethyl, 2-propoxyethyl, 3-propoxypropyl, butoxymethyl, tert-butoxymethyl, isobutoxymethyl, sec-butoxymethyl, and pentyloxymethyl).

Useful haloalkoxy groups include oxygen substituted by one of the C₁₋₁₀ haloalkyl groups, and preferably one of the C₁₋₆ haloalkyl groups, mentioned above (e.g., fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 2,2,2-trifluoroethoxy).

Useful (cycloalkyl)alkyl groups include any of the above-mentioned C₁₋₁₀ alkyl groups, and preferably any of the above-mentioned C₁₋₆ alkyl groups, substituted with any of the above-mentioned cycloalkyl groups (e.g., (cyclopropyl)methyl, 2-(cyclopropyl)ethyl, (cyclopropyl)propyl, (cyclobutyl)methyl, (cyclopentyl)methyl, and (cyclohexyl)methyl).

Useful aryl groups are C₆₋₁₄ aryl, especially C₆₋₁₀ aryl. Typical C₆₋₁₄ aryl groups include phenyl, naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups, more preferably phenyl, naphthyl, and biphenyl groups.

Useful aryloxy groups include oxygen substituted by one of the aryl groups mentioned above (e.g., phenoxy).

Useful arylalkyl or aralkyl groups include any of the above-mentioned C₁₋₁₀ alkyl groups, and preferably any of the above-mentioned C₁₋₆ alkyl groups, substituted by any of the above-mentioned aryl groups (e.g., benzyl and phenethyl).

Useful arylalkenyl groups include any of the above-mentioned C₂₋₆ alkenyl groups substituted by any of the above-mentioned aryl groups (e.g., phenylethenyl).

Useful arylalkynyl groups include any of the above-mentioned C₂₋₆ alkynyl groups substituted by any of the above-mentioned aryl groups (e.g., phenylethynyl).

Useful aralkyloxy or arylalkoxy groups include oxygen substituted by one of the above-mentioned arylalkyl groups, such as ar(C₁₋₆)alkyl groups (e.g., benzyloxy).

The term "heteroaryl" or "heteroaromatic" as employed herein refers to groups having 5 to 14 ring atoms, with 6, 10 or 14 π electrons shared in a cyclic array, and containing carbon atoms and 1, 2, or 3 oxygen, nitrogen or sulfur heteroatoms, or 4 nitrogen atoms. In one embodiment, the heteroaryl group is a 5- to 10-membered heteroaryl group. Examples of

heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, benzofuryl, pyranyl, isobenzofuranyl, benzooxazolyl, chromenyl, xanthenyl, 2*H*-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, 3*H*-indolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, cinnolinyl, quinazolinyl, pteridinyl, 4*aH*-carbazolyl, carbazolyl, β -carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, thiazolyl, isothiazolyl, phenothiazolyl, isoxazolyl, furazanyl, and phenoxazinyl. Typical heteroaryl groups include thienyl (e.g., thien-2-yl and thien-3-yl), furyl (e.g., 2-furyl and 3-furyl), pyrrolyl (e.g., pyrrol-1-yl, 1*H*-pyrrol-2-yl and 1*H*-pyrrol-3-yl), imidazolyl (e.g., imidazol-1-yl, 1*H*-imidazol-2-yl and 1*H*-imidazol-4-yl), tetrazolyl (e.g., tetrazol-1-yl and tetrazol-5-yl), pyrazolyl (e.g., 1*H*-pyrazol-3-yl, 1*H*-pyrazol-4-yl, and 1*H*-pyrazol-5-yl), pyridyl (e.g., pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, and pyrimidin-5-yl), thiazolyl (e.g., thiazol-2-yl, thiazol-4-yl, and thiazol-5-yl), isothiazolyl (e.g., isothiazol-3-yl, isothiazol-4-yl, and isothiazol-5-yl), oxazolyl (e.g., oxazol-2-yl, oxazol-4-yl, and oxazol-5-yl) and isoxazolyl (e.g., isoxazol-3-yl, isoxazol-4-yl, and isoxazol-5-yl). A 5-membered heteroaryl can contain up to 4 heteroatoms. A 6-membered heteroaryl can contain up to 3 heteroatoms. Each heteroatom is independently selected from nitrogen, oxygen and sulfur.

The terms "heterocyclic" and "heterocyclo" are used herein to mean saturated or partially unsaturated 3-7 membered monocyclic, or 7-10 membered bicyclic ring system, which consist of carbon atoms and from one to four heteroatoms independently selected from the group consisting of O, N, and S, wherein the nitrogen and sulfur heteroatoms can be optionally oxidized, the nitrogen can be optionally quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring, and wherein the heterocyclic ring can be substituted on a carbon atom or on a nitrogen atom if the resulting compound is stable. In one embodiment, the 3- to 7-membered monocyclic heterocyclic ring is either a saturated, or unsaturated non-aromatic ring. A 3-membered heterocyclo can contain up to 1 heteroatom, a 4-membered heterocyclo can contain up to 2 heteroatoms, a 5-membered heterocyclo can contain up to 4 heteroatoms, a 6-membered heterocyclo can contain up to 4 heteroatoms, and a 7-membered heterocyclo can contain up to 5 heteroatoms. Each heteroatom is independently selected from nitrogen, which can be quaternized; oxygen; and sulfur, including sulfoxide and sulfone. The 3- to 7-membered heterocyclo can be attached via a nitrogen or carbon atom. A 7- to 10-membered bicyclic

heterocyclo contains from 1 to 4 heteroatoms independently selected from nitrogen, which can be quaternized; oxygen; and sulfur, including sulfoxide and sulfone. The 7- to 10-membered bicyclic heterocyclo can be attached via a nitrogen or carbon atom. Examples of the heterocyclic rings include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, imidazoliny, pyrazolidinyl, tetrahydrofuranyl, oxazolidinyl, 2-oxooxazolidinyl, tetrahydrothienyl, imidazolidinyl, hexahydropyrimidinyl, and benzodiazepines.

Useful (heterocyclo)alkyl groups include any of the above-mentioned C₁₋₁₀ alkyl groups, and preferably any of the above-mentioned C₁₋₆ alkyl groups, substituted by any of the above-mentioned heterocyclic groups (e.g., (pyrrolidin-2-yl)methyl, (pyrrolidin-1-yl)methyl, (piperidin-1-yl)methyl, (morpholin-4-yl)methyl, (2-oxooxazolidin-4-yl)methyl, 2-(2-oxooxazolidin-4-yl)ethyl, (2-oxo-imidazolidin-1-yl)methyl, (2-oxo-imidazolidin-1-yl)ethyl, and (2-oxo-imidazolidin-1-yl)propyl).

As used herein, the term "amino" or "amino group" refers to -NH₂.

Useful aminoalkyl groups include any of the above-mentioned C₁₋₁₀ alkyl groups, and preferably any of the above-mentioned C₁₋₆ alkyl groups, substituted with one or more amino group.

Useful alkylamino and dialkylamino groups are —NHR¹⁶ and —NR¹⁶R¹⁷, respectively, wherein R¹⁶ and R¹⁷ are each independently selected from a C₁₋₁₀ alkyl group.

As used herein, the term "aminocarbonyl" refers to -C(=O)NH₂.

Useful alkylcarbonyl groups include a carbonyl group, i.e., -C(=O)-, substituted by any of the above-mentioned C₁₋₁₀ alkyl groups.

Useful alkoxy carbonyl groups include a carbonyl group substituted by any of the above-mentioned alkoxy groups (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, iso-propoxycarbonyl, butoxycarbonyl, tert-butoxycarbonyl, iso-butoxycarbonyl, sec-butoxycarbonyl, and pentyloxycarbonyl).

Useful alkylcarbonyloxy or acyloxy groups include oxygen substituted by one of the above-mentioned alkylcarbonyl groups.

Useful alkylcarbonylamino or acylamino groups include any of the above-mentioned alkylcarbonyl groups attached to an amino nitrogen, such as methylcarbonylamino.

As used herein, the term "carboxamido" refers to a radical of formula -C(=O)NR¹⁸R¹⁹, wherein R¹⁸ and R¹⁹ are each independently hydrogen, optionally substituted C₁₋₁₀ alkyl, or optionally substituted aryl. Exemplary carboxamido groups include -CONH₂, -CON(H)CH₃, -CON(CH₃)₂, and -CON(H)Ph.

As used herein, the term "sulfonamido" refers to a radical of formula $-\text{SO}_2\text{NR}^{20}\text{R}^{21}$, wherein R^{20} and R^{21} are each independently hydrogen, optionally substituted C_{1-10} alkyl, or optionally substituted aryl. Exemplary sulfonamido groups include $-\text{SO}_2\text{NH}_2$, $-\text{SO}_2\text{N}(\text{H})\text{CH}_3$, and $-\text{SO}_2\text{N}(\text{H})\text{Ph}$.

5 As used herein, the term "thiol" refers to $-\text{SH}$.

Useful mercaptoalkyl groups include any of the above-mentioned C_{1-10} alkyl groups, and preferably any of the above-mentioned C_{1-6} alkyl groups, substituted by a $-\text{SH}$ group.

As used herein, the term "carboxy" refers to $-\text{COOH}$.

10 Useful carboxyalkyl groups include any of the above-mentioned C_{1-10} alkyl groups, and preferably any of the above-mentioned C_{1-6} alkyl groups, substituted by $-\text{COOH}$.

As used herein, the terms "hydroxyl" or "hydroxy" refer to $-\text{OH}$.

As used herein, the term "cyano" refers to $-\text{CN}$.

As used herein, the term "nitro" refers to $-\text{NO}_2$.

As used herein, the term "ureido" refers to $-\text{NH}-\text{C}(=\text{O})-\text{NH}_2$.

15 As used herein, the term "azido" refers to $-\text{N}_3$.


The term "ambient temperature" as used herein means the temperature of the surroundings. The ambient temperature indoors is the same as room temperature, which is from about 20°C to about 25°C .

20 The term "about," as used herein in connection with a measured quantity, refers to the normal variations in that measured quantity, as expected by the skilled artisan making the measurement and exercising a level of care commensurate with the objective of measurement and the precision of the measuring equipment. Typically, the term "about" includes the recited number $\pm 10\%$. Thus, "about 10" means 9 to 11.

25 As used herein, the term "optionally substituted" refers to a group that may be unsubstituted or substituted.

As used herein, the term "optionally fused to a phenyl ring" refers to a group that may have a fused phenyl ring or may not have a fused phenyl ring.

30 As used herein, the phrase "two adjacent carbon atoms of said cycloalkyl or cycloalkenyl rings are fused to a phenyl ring" refers to a group where any of the above-mentioned cycloalkyl and cycloalkenyl groups that have a fused phenyl ring. Such groups include, for example,



Optional substituents on optionally substituted groups, when not otherwise indicated, include one or more groups, typically 1, 2, or 3 groups, independently selected from the group consisting of halo, halo(C₁₋₆)alkyl, aryl, heterocyclo, cycloalkyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl(C₁₋₆)alkyl, aryl(C₂₋₆)alkenyl, aryl(C₂₋₆)alkynyl, cycloalkyl(C₁₋₆)alkyl, heterocyclo(C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, amino(C₁₋₆)alkyl, carboxy(C₁₋₆)alkyl, alkoxy(C₁₋₆)alkyl, nitro, amino, ureido, cyano, alkylcarbonylamino, hydroxy, thiol, alkylcarbonyloxy, aryloxy, ar(C₁₋₆)alkyloxy, carboxamido, sulfonamido, azido, C₁₋₆ alkoxy, halo(C₁₋₆)alkoxy, carboxy, aminocarbonyl, (=O), and mercapto(C₁₋₆)alkyl groups mentioned above. Preferred optional substituents include halo, halo(C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, amino(C₁₋₆)alkyl, hydroxy, nitro, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo(C₁₋₆)alkoxy, and amino.

Compounds of the Invention encompass all the salts of the disclosed compounds of Formulae **I-VII**. The present invention preferably includes all non-toxic pharmaceutically acceptable salts thereof of the disclosed compounds. Examples of pharmaceutically acceptable addition salts include inorganic and organic acid addition salts and basic salts. The pharmaceutically acceptable salts include, but are not limited to, metal salts such as sodium salt, potassium salt, cesium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt and the like; inorganic acid salts such as hydrochloride, hydrobromide, phosphate, sulphate and the like; organic acid salts such as citrate, lactate, tartrate, maleate, fumarate, mandelate, acetate, dichloroacetate, trifluoroacetate, oxalate, formate and the like; sulfonates such as methanesulfonate, benzenesulfonate, p-toluenesulfonate and the like; and amino acid salts such as arginate, aspartate, glutamate and the like.

Acid addition salts can be formed by mixing a solution of the particular compound of the present invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid, dichloroacetic acid, or the like. Basic salts can be formed by mixing a solution of the compound of the present invention with a solution

of a pharmaceutically acceptable non-toxic base such as sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate and the like.

Compounds of the Invention also encompass solvates of any of the disclosed compounds of Formulae **I-VII**. Solvates typically do not significantly alter the physiological activity or toxicity of the compounds, and as such may function as pharmacological equivalents.

The term “solvate” as used herein is a combination, physical association and/or solvation of a compound of the present invention with a solvent molecule such as, e.g. a disolvate, monosolvate or hemisolvate, where the ratio of solvent molecule to compound of the present invention is about 2:1, about 1:1 or about 1:2, respectively. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate can be isolated, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. Thus, “solvate” encompasses both solution-phase and isolatable solvates. Compounds of the Invention may be present as solvated forms with a pharmaceutically acceptable solvent, such as water, methanol, ethanol, and the like, and it is intended that the invention includes both solvated and unsolvated forms of compounds of any of Formulae **I-VII**. One type of solvate is a hydrate.

A “hydrate” relates to a particular subgroup of solvates where the solvent molecule is water. Solvates typically can function as pharmacological equivalents.

Preparation of solvates is known in the art. See, for example, M. Caira *et al.*, *J. Pharmaceut. Sci.*, 93(3):601-611 (2004), which describes the preparation of solvates of fluconazole with ethyl acetate and with water. Similar preparation of solvates, hemisolvates, hydrates, and the like are described by E.C. van Tonder *et al.*, *AAPS Pharm. Sci. Tech.*, 5(1):Article 12 (2004), and A.L. Bingham *et al.*, *Chem. Commun.*: 603-604 (2001). A typical, non-limiting, process of preparing a solvate would involve dissolving a compound of any of Formulae **I-VII** in a desired solvent (organic, water, or a mixture thereof) at temperatures above about 20 °C to about 25 °C, then cooling the solution at a rate sufficient to form crystals, and isolating the crystals by known methods, e.g., filtration. Analytical techniques such as infrared spectroscopy can be used to confirm the presence of the solvent in a crystal of the solvate.

Compounds of the Invention can be isotopically-labeled (*i.e.*, radio-labeled). Examples of isotopes that can be incorporated into the disclosed compounds include isotopes

of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F and ^{36}Cl , respectively, and preferably ^3H , ^{11}C , and ^{14}C . Isotopically-labeled Compounds of the Invention can be prepared by methods known in the art in view of this disclosure. For example, tritiated Compounds of the
5 Invention can be prepared by introducing tritium into the particular compound by catalytic dehalogenation with tritium. This method may include reacting a suitable halogen-substituted precursor of a Compound of the Invention with tritium gas in the presence of an appropriate catalyst such as Pd/C in the presence of a base. Other suitable methods for preparing tritiated compounds can be found in Filer, *Isotopes in the Physical and Biomedical*
10 *Sciences, Vol. 1, Labeled Compounds (Part A)*, Chapter 6 (1987). ^{14}C -labeled compounds can be prepared by employing starting materials having a ^{14}C carbon.

Isotopically labeled Compounds of the Invention, as well as the pharmaceutically acceptable salts and solvates thereof, can be used as radioligands to test for the binding of compounds to an opioid receptor. For example, a radio-labeled Compound of the Invention
15 can be used to characterize specific binding of a test or candidate compound to the receptor. Binding assays utilizing such radio-labeled compounds can provide an *in vitro* alternative to animal testing for the evaluation of chemical structure-activity relationships. For example, the receptor assay may be performed at a fixed concentration of a radiolabeled Compound of the Invention and at increasing concentrations of a test compound in a competition assay.

In a non-limiting embodiment, the present invention provides a method for screening a candidate compound for the ability to bind to an opioid receptor, comprising a) introducing a fixed concentration of a radio-labeled Compound of the Invention to the receptor under conditions that permit binding of the radio-labeled compound to the receptor to form a complex; b) titrating the complex with a candidate compound; and c) determining the binding
20 of the candidate compound to said receptor.

Some of the compounds disclosed herein may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms, such as epimers. The present invention is meant to encompass the uses of all such possible forms, as well as their racemic and resolved forms and mixtures thereof. The individual
30 enantiomers may be separated according to methods known to those of ordinary skill in the art in view of the present disclosure. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is

intended that they include both E and Z geometric isomers. All tautomers are intended to be encompassed by the present invention as well.

As used herein, the term "stereoisomers" is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes enantiomers
5 and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers).

The term "chiral center" refers to a carbon atom to which four different groups are attached.

The term "epimer" refers to diastereomers that have opposite configuration at only
10 one of two or more tetrahedral stereogenic centres present in the respective molecular entities.

The term "stereogenic center" is an atom, bearing groups such that an interchanging of any two groups leads to a stereoisomer.

The terms "enantiomer" and "enantiomeric" refer to a molecule that cannot be superimposed on its mirror image and hence is optically active wherein the enantiomer
15 rotates the plane of polarized light in one direction and its mirror image compound rotates the plane of polarized light in the opposite direction.

The term "racemic" refers to a mixture of equal parts of enantiomers and which mixture is optically inactive.

The term "resolution" refers to the separation or concentration or depletion of one of
20 the two enantiomeric forms of a molecule.

The terms "a" and "an" refer to one or more.

The term "treating" or "treatment" refers to administering a therapy in an amount, manner, or mode effective to improve a condition, symptom, or parameter associated with a disorder or to prevent progression of a disorder, to either a statistically significant degree or
25 to a degree detectable to one skilled in the art. An effective amount, manner, or mode can vary depending on the subject and may be tailored to the patient.

Open terms such as "include," "including," "contain," "containing" and the like mean "comprising."

As used herein, compounds that bind to receptors and mimic the regulatory effects of
30 endogenous ligands are defined as "agonists". Compounds that bind to receptors and are only partly effective as agonists are defined as "partial agonists". Compounds that bind to a receptor but produce no regulatory effect, but rather block the binding of ligands to the receptor are defined as "antagonists". (Ross and Kenakin, "Ch. 2: Pharmacodynamics:

Mechanisms of Drug Action and the Relationship Between Drug Concentration and Effect”, pp. 31-32, in *Goodman & Gilman’s the Pharmacological Basis of Therapeutics*, 10th Ed. (J.G. Hardman, L.E. Limbird and A. Goodman-Gilman eds., 2001)).

In certain embodiments, the Compound of the Invention is an agonist at one or more of the μ , δ and/or κ opioid receptors. In certain non-limiting embodiments, the Compound of the Invention produces fewer side effects and/or less severe side effects than currently available analgesic opioid compounds when administered at doses producing equivalent levels of analgesia and/or anti-hyperalgesia. In certain embodiments, the Compound of the Invention is an agonist at ORL-1 opioid receptor.

In certain embodiments, Compounds of the Invention can be used in combination with at least one other therapeutic agent. The other therapeutic agent can be, but is not limited to, a μ -opioid agonist, a non-opioid analgesic, a non-steroidal anti-inflammatory agent, a Cox-II inhibitor, an anti-emetic, a β -adrenergic blocker, an anticonvulsant, an antidepressant, a Ca^{2+} -channel blocker, an anticancer agent, or a mixture thereof.

Compounds of the Invention potently bind to the μ and/or κ and/or δ and/or ORL-1 opioid receptors. Compounds of the Invention can be modulators at the μ and/or κ and/or δ and/or ORL-1 opioid receptors, and therefore Compounds of the Invention can be used/administered to treat, ameliorate, or prevent pain.

In some embodiments, Compounds of the Invention are antagonists of one or more opioid receptors. In another embodiment, Compounds of the Invention are antagonists of the μ and/or κ opioid receptors.

In some embodiments, Compounds of the Invention are partial agonists of one or more opioid receptors. In another embodiment, Compounds of the Invention are partial agonists of the μ and/or κ opioid receptors.

In another embodiment, Compounds of the Invention are agonists of one or more opioid receptors. In another embodiment, Compounds of the Invention are agonists of the μ and/or κ opioid receptors.

In some embodiments, Compounds of the Invention have both: (i) antagonist activity at the ORL-1 receptor; and (ii) agonist activity at one or more of the μ , δ and/or κ receptors.

In other embodiments, Compounds of the Invention have both: (i) antagonist activity at the ORL-1 receptor; and (ii) agonist activity at the μ receptor. In another embodiment, Compounds of the Invention have both: (i) antagonist activity at the μ receptor; and (ii) agonist activity at the κ receptor. In another embodiment, Compounds of the Invention have:

(i) antagonist activity at the ORL-1 receptor; (ii) antagonist activity at the μ receptor; and (iii) agonist activity at the κ receptor. In another embodiment, Compounds of the Invention have: (i) antagonist activity at the μ receptor; (ii) agonist activity at the κ receptor; and (iii) antagonist activity at the δ receptor.

5 Compounds of the Invention that are antagonists of the μ -opioid receptor or agonists of κ -opioid receptor, or both, can be used/administered to treat or ameliorate constipation. Compounds of the Invention that are agonists of μ -opioid receptor can be used/administered to treat or ameliorate diarrhea.

10 Compounds of the Invention can be used to treat or prevent acute, chronic pain (which includes but is not limited to, neuropathic pain, postoperative pain, and inflammatory pain), or surgical pain. Examples of pain that can be treated or prevented using a Compound of the Invention include, but are not limited to, cancer pain, neuropathic pain, labor pain, myocardial infarction pain, pancreatic pain, colic pain, post-operative pain, headache pain, muscle pain, arthritic pain, and pain associated with a periodontal disease, including
15 gingivitis and periodontitis.

 Acute pain includes, but is not limited to, perioperative pain, postoperative pain, post-traumatic pain, acute disease related pain, and pain related to diagnostic procedures, orthopedic manipulations, and myocardial infarction. Acute pain in the perioperative setting includes pain because of pre-existing disease, the surgical procedure, e.g., associated drains,
20 chest or nasogastric tubes, or complications, or a combination of disease-related and procedure-related sources.

 Chronic pain includes, but is not limited to, inflammatory pain, postoperative pain, cancer pain, osteoarthritis pain associated with metastatic cancer, trigeminal neuralgia, acute herpetic and postherpetic neuralgia, diabetic neuropathy, causalgia, brachial plexus avulsion,
25 occipital neuralgia, reflex sympathetic dystrophy, fibromyalgia, gout, phantom limb pain, burn pain, and other forms of neuralgia, neuropathic, and idiopathic pain syndromes.

 Compounds of the Invention can be used to treat or prevent pain associated with inflammation or with an inflammatory disease in a patient. Such pain can arise where there is an inflammation of the body tissue which can be a local inflammatory response or a systemic
30 inflammation. For example, a Compound of the Invention can be used to treat or prevent pain associated with inflammatory diseases including, but not limited to, organ transplant rejection; reoxygenation injury resulting from organ transplantation (see Grupp *et al.*, *J. Mol. Cell Cardiol.* 31:297-303 (1999)) including, but not limited to, transplantation of the heart,

lung, liver, or kidney; chronic inflammatory diseases of the joints, including arthritis, rheumatoid arthritis, osteoarthritis and bone diseases associated with increased bone resorption; inflammatory bowel diseases, such as ileitis, ulcerative colitis, Barrett's syndrome, and Crohn's disease; inflammatory lung diseases, such as asthma, adult respiratory distress syndrome, and chronic obstructive airway disease; inflammatory diseases of the eye, including corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis and endophthalmitis; chronic inflammatory disease of the gum, including gingivitis and periodontitis; tuberculosis; leprosy; inflammatory diseases of the kidney, including uremic complications, glomerulonephritis and nephrosis; inflammatory disease of the skin, including sclerodermatitis, psoriasis and eczema; inflammatory diseases of the central nervous system, including chronic demyelinating diseases of the nervous system, multiple sclerosis, AIDS-related neurodegeneration and Alzheimer's disease, infectious meningitis, encephalomyelitis, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and viral or autoimmune encephalitis; autoimmune diseases, including Type I and Type II diabetes mellitus; diabetic complications, including, but not limited to, diabetic cataract, glaucoma, retinopathy, nephropathy (such as microalbuminuria and progressive diabetic nephropathy), gangrene of the feet, atherosclerotic coronary arterial disease, peripheral arterial disease, nonketotic hyperglycemic-hyperosmolar coma, foot ulcers, joint problems, and a skin or mucous membrane complication (such as an infection, a shin spot, a candidal infection or necrobiosis lipoidica diabetorum), immune-complex vasculitis, and systemic lupus erythematosus (SLE); inflammatory disease of the heart, such as cardiomyopathy, ischemic heart disease hypercholesterolemia, and arteriosclerosis; as well as various other diseases that can have significant inflammatory components, including preeclampsia, chronic liver failure, brain and spinal cord trauma, and cancer.

Compounds of the Invention can also be used to treat or prevent pain associated with inflammatory disease that can, for example, be a systemic inflammation of the body, exemplified by gram-positive or gram negative shock, hemorrhagic or anaphylactic shock, or shock induced by cancer chemotherapy in response to pro-inflammatory cytokines, *e.g.*, shock associated with pro-inflammatory cytokines. Such shock can be induced, *e.g.*, by a chemotherapeutic agent that is administered as a treatment for cancer.

Compounds of the Invention can be used to treat or prevent pain associated with nerve injury (*i.e.*, neuropathic pain). Chronic neuropathic pain is a heterogeneous disease state with an unclear etiology. In chronic pain, the pain can be mediated by multiple mechanisms. This

type of pain generally arises from injury to the peripheral or central nervous tissue. The syndromes include pain associated with spinal cord injury, multiple sclerosis, post-herpetic neuralgia, trigeminal neuralgia, phantom pain, causalgia, and reflex sympathetic dystrophy and lower back pain. The chronic pain is different from acute pain in that chronic

5 neuropathic pain patients suffer the abnormal pain sensations that can be described as spontaneous pain, continuous superficial burning and/or deep aching pain. The pain can be evoked by heat-, cold-, and mechano-hyperalgesia or by heat-, cold-, or mechano-allodynia. Chronic neuropathic pain can be caused by injury or infection of peripheral sensory nerves. It includes, but is not limited to pain from peripheral nerve trauma, herpes virus infection,

10 diabetes mellitus, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis.

Neuropathic pain can also be caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiencies. Stroke (spinal or brain) and spinal cord injury can also induce neuropathic pain. Cancer-related neuropathic pain results from tumor growth compression of adjacent nerves, brain, or

15 spinal cord. In addition, cancer treatments, including chemotherapy and radiation therapy, can cause nerve injury. Neuropathic pain includes but is not limited to pain caused by nerve injury such as, for example, the pain from which diabetics suffer.

Compounds of the Invention can be used to treat or prevent pain associated with migraine including, but not limited to, migraine without aura ("common migraine"), migraine

20 with aura ("classic migraine"), migraine without headache, basilar migraine, familial hemiplegic migraine, migrainous infarction, and migraine with prolonged aura.

Compounds of the Invention can also be used as an agent to treat withdrawal from alcohol addiction or drug addiction; as an agent to treat or prevent addictive disorders; an agent to treat a pruritic condition; and in treating or ameliorating constipation and diarrhea.

25 The present invention is also directed to the use of a compound represented by any of defined Formulae **I-VI**, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treating a disorder responsive to the modulation of one or more opioids receptors (e.g., any of the disorders listed above) in a patient suffering from said disorder.

30 Furthermore, the present invention is directed to a method of modulating, in particular activating, one or more opioid receptors in a patient in need thereof, said method comprising administering to the patient at least one compound represented by any of defined Formulae **I-VI**, or a pharmaceutically acceptable salt or solvate thereof.

The present invention is also directed to the use of a compound represented by any of defined Formulae I-VI, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament, in particular a medicament for modulating, in particular activating, one or more opioid receptors, in a patient in need thereof.


5

Synthesis of Compounds

Compounds of the Invention can be prepared using methods known to those skilled in the art in view of this disclosure, or by the illustrative methods shown in the schemes below. Additional methods of synthesis are described and illustrated in the working examples set forth below.

10

Scheme 1



In Scheme 1, R^1 - R^3 , R^6 , and R^7 are as defined for Formula I. R is an optionally substituted alkyl group. The deprotection can be performed when R^1 is $-O$ -PG using methods known in the art, for example, by reacting with BBr_3 when PG is a methyl group


The starting **Compound A** can be prepared, for example, as described in Hupp C. D., *et al.*, *Tetrahedron Letters* 51:2359-2361 (2010) and Ida Y., *et al.*, *Bioorganic & Medical Chemistry* 20:949-961 (2012).

Compound A is first treated with methyl formate, in the presence of a suitable base such as sodium ethoxide, in a suitable solvent such as diethyl ether. Subsequent treatment with methyl cyanoacetate in a suitable solvent such as MeOH gives **Compound B**. Using literature methods known by one skilled in the art (e.g. Greene, T.W. "Protective Groups in Organic Synthesis", J. Wiley & Sons, NY, 1981), **Compound B** is deprotected to give **Compound C** when R^2 is an alkoxycarbonyl, such as as tert-butoxy carbonyl. In the alternative, **Compound B** is treated with ammonia in MeOH to give **Compound D**. Also in the alternative, **Compound B** is hydrolyzed in the presence of a suitable base, such as lithium hydroxide, in a suitable solvent, such as THF, to give **Compound F**. **Compound F** can be functionalized with suitable reagents, such as primary and secondary amines, under peptide coupling conditions with a suitable peptide coupling agent, such as 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), in the presence of a suitable base, such as DIEA, in a suitable solvent, such as dimethylformamide (DMF), to obtain **Compound G**.

Compounds of Formula IV can be prepared analogously starting from the opposite isomer of compound A above with respect to R^3 , which can be prepared, for example, as described in Polazzi J. O., *et al.*, *J. Med. Chem.* 23:174-179 (1980).


Compounds of the Invention, where R^4 is alkyl can be prepared, for example, as described in Scheme 2.

Scheme 2




In Scheme 2, R^1 - R^3 and Z are as described for Formula I and R' is alkyl. X is halogen, such as chlorine or bromine, and the base can be, for example, potassium carbonate (K_2CO_3).

The opposite isomers of the compounds described in Schemes 1 and 2 can be prepared starting from ketone **A'**:



Ketone **A'** can be prepared according methods described in the art, such as, for example, in US 2009/0156818, US 2009/0156820, and Hupp C. D., *et al.* (*supra*). Accordingly, for example, ketone **A'**, where R^1 is OMe, can be prepared as described in Scheme 3 starting from CAS# 6080-33-7:



15

In vitro Assay Protocols

μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ -opioid receptors can use 0.3 nM [3H]-diprenorphine (Perkin Elmer,

Shelton, CT), with 5 mg membrane protein/well in a final volume of 500 μ l binding buffer (10 mM MgCl_2 , 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions are carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions are conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions are terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, CT), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, CT) followed by performing three filtration washes with 500 μ l of ice-cold binding buffer. Filter plates are subsequently dried at 50 $^{\circ}\text{C}$ for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, CT) was added (50 μ l/well), and plates are counted using a Packard Top-Count for 1 min/well. The data can be analyzed using the one-site competition curve fitting functions in GraphPad PRISMTM v. 3.0 or higher (San Diego, Calif.), or an in-house function for one-site competition curve-fitting.

μ -Opioid Receptor Binding Data: Generally, the lower the K_i value, the more effective Compounds of the Invention will be at treating or preventing pain or another Condition. Typically, Compounds of the Invention exhibit a K_i (nM) of about 1000 or less for binding to μ -opioid receptors. In one embodiment, Compounds of the Invention exhibit a K_i (nM) of about 300 or less for binding to μ -opioid receptors. In another embodiment, Compounds of the Invention exhibit a K_i (nM) of about 100 or less for binding to μ -opioid receptors. In another embodiment, Compounds of the Invention exhibit a K_i (nM) of about 10 or less for binding to μ -opioid receptors. In still another embodiment, Compounds of the Invention exhibit a K_i (nM) of about 1 or less for binding to μ -opioid receptors. In still another embodiment, Compounds of the Invention exhibit a K_i (nM) of about 0.1 or less for binding to μ -opioid receptors.

μ -Opioid Receptor Functional Assay Procedures: [³⁵S]GTP γ S functional assays were conducted using freshly thawed μ -receptor membranes prepared in-house from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background, or purchased from a commercial source (Perkin Elmer, Shelton, CT; or DiscovRx, Fremont, CA). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl_2 , 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [³⁵S]GTP γ S (0.20 nM; Perkin Elmer, Shelton, CT). The prepared membrane solution (190 μ l/well) was transferred to 96-shallow well polypropylene plates containing 10 μ l of 20x concentrated stock solutions of the agonist [D-Ala², N-methyl-Phe⁴

Gly-ol⁵]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25°C with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, CT) using a 96-well tissue harvester (Perkin Elmer, Shelton, CT) followed by three filtration washes with 200 µl of ice-cold wash buffer (10 mM NaH₂PO₄, 10 mM Na₂HPO₄, pH 7.4). Filter plates were subsequently dried at 50°C for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, CT) was added (50 µl/well) and plates were counted using a Packard Top-Count for 1 min/well. Data were analyzed using the sigmoidal dose-response curve fitting functions in GraphPad PRISM v. 3.0, or an in-house function for non-linear, sigmoidal dose-response curve-fitting.

µ-Opioid Receptor Functional Data: µ GTP EC₅₀ is the concentration of a compound providing 50% of the maximal response for the compound at a µ-opioid receptor. Certain Compounds of the Invention can exhibit a µ GTP EC₅₀ (nM) of about 20,000 or less; or about 10,000 or less. In certain embodiments, Compounds of the Invention exhibit a µ GTP EC₅₀ (nM) of about 5000 or less. In certain embodiments, Compounds of the Invention exhibit a µ GTP EC₅₀ (nM) of about 2000 or less; or about 1000 or less; or about 100 or less; or about 10 or less; or about 1 or less; or about 0.1 or less.

µ GTP E_{max} (%) is the maximal effect elicited by a compound relative to the effect elicited by DAMGO, a standard µ agonist. Generally, the µ GTP E_{max} (%) value measures the efficacy of a compound to treat or prevent pain or other Conditions. Typically, Compounds of the Invention exhibit a µ GTP E_{max} (%) of greater than about 10%; or greater than about 20%. In certain embodiments, Compounds of the Invention exhibit a µ GTP E_{max} (%) of greater than about 50%; or greater than about 65%; or greater than about 75%; or greater than about 85%; or greater than about 100%.

κ-Opioid Receptor Binding Assay Procedures: Membranes from HEK-293 cells, CHO or U-2 OS cells expressing the recombinant human kappa opioid receptor (κ) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl₂, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000 x g for 15 min at 4°C and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of κ receptor membranes were stored at -80 °C.

Radioligand dose displacement assays used 0.4 nM [³H]-U69,593 (GE Healthcare, Piscataway, NJ; 40 Ci/mmol) with 15 µg membrane protein (recombinant κ opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 µl binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 µM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25°C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, CT) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, CT) followed by five filtration washes with 200 µl ice-cold binding buffer. Filter plates were subsequently dried at 50°C for 1-2 hours. Fifty µl/well scintillation cocktail (Perkin Elmer, Shelton, CT) was added and plates were counted in a Packard Top-Count for 1 min/well.

κ-Opioid Receptor Binding Data: In certain embodiments, Compounds of the Invention exhibit a K_i (nM) for κ receptors of about 10,000 or more (which, for purposes of this invention, is interpreted as having no binding to the κ receptors). Certain Compounds of the Invention exhibit a K_i (nM) of about 20,000 or less for κ receptors. In certain embodiments, Compounds of the Invention exhibit a K_i (nM) of about 10,000 or less; or about 5000 or less; or about 1000 or less; or about 500 or less; or about 450 or less; or about 350 or less; or about 200 or less; or about 100 or less; or about 50 or less; or about 10 or less; or about 1 or less; or about 0.1 or less for κ receptors.

κ-Opioid Receptor Functional Assay Procedures: Functional [³⁵S]GTPγS binding assays were conducted as follows. κ opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 µg/µl κ membrane protein (in-house), 10 µg/mL saponin, 3 µM GDP and 0.20 nM [³⁵S]GTPγS to binding buffer (100 mM NaCl, 10 mM MgCl₂, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 µl/well) was transferred to 96-shallow well polypropylene plates containing 10 µl of 20x concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25°C with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, CT) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 µl ice-cold binding buffer (10 mM NaH₂PO₄, 10 mM Na₂HPO₄, pH 7.4). Filter plates were subsequently dried at 50°C for 2-3 hours. Fifty µl/well scintillation cocktail (Perkin Elmer, Shelton, CT) was added and plates were counted in a Packard Top-Count for 1 min/well.

κ-Opioid Receptor Functional Data: κ GTP EC₅₀ is the concentration of a compound providing 50% of the maximal response for the compound at a κ receptor. Certain Compounds of the Invention exhibit a κ GTP EC₅₀ (nM) of about 20,000 or less to stimulate κ opioid receptor function. In certain embodiments, Compounds of the Invention exhibit a κ GTP EC₅₀ (nM) of about 10,000 or less; or about 5000 or less; or about 2000 or less; or about 1500 or less; or about 1000 or less; or about 600 or less; or about 100 or less; or about 50 or less; or about 25 or less; or about 10 or less; or about 1 or less; or about 0.1 or less.

κ GTP E_{max} (%) is the maximal effect elicited by a compound relative to the effect elicited by U69,593. Certain Compounds of the Invention exhibit a κ GTP E_{max} (%) of greater than about 1%; or greater than about 5%; or greater than about 10%; or greater than about 20%. In certain embodiments, Compounds of the Invention exhibit a κ GTP E_{max} (%) of greater than about 50%; or greater than about 75%; or greater than about 90%; or greater than about 100%.

δ-Opioid Receptor Binding Assay Procedures: δ-Opioid Receptor Binding Assay Procedures can be conducted as follows. Radioligand dose-displacement assays used 0.3 nM [³H]-Naltrindole (Perkin Elmer, Shelton, CT; 33.0 Ci/mmol) with 5 μg membrane protein (Perkin Elmer, Shelton, CT) in a final volume of 500 μl binding buffer (5 mM MgCl₂, 5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding is determined in the presence of 25 μM unlabeled naloxone. All reactions are performed in 96-deep well polypropylene plates for 1 hour at a temperature of about 25°C. Binding reactions are terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, CT) presoaked in 0.5% polyethylenimine (Sigma). Harvesting is performed using a 96-well tissue harvester (Perkin Elmer, Shelton, CT) followed by five filtration washes with 500 μl ice-cold binding buffer. Filter plates are subsequently dried at 50°C for 1-2 hours. Fifty μl/well scintillation cocktail (Perkin Elmer, Shelton, CT) is added and plates are counted in a Packard Top-Count for 1 min/well.

δ-Opioid Receptor Binding Data: In certain embodiments, Compounds of the Invention exhibit a K_i (nM) for δ receptors of about 10,000 or more (which, for the purposes of this invention, is interpreted as having no binding to the δ receptors). Certain Compounds of the Invention exhibit a K_i (nM) of about 20,000 or less for δ receptors. In one embodiment, Compounds of the Invention exhibit a K_i (nM) of about 10,000 or less; or of about 9000 or less for δ receptors. In another embodiment, Compounds of the Invention exhibit a K_i (nM) of about 7500 or less; or of about 6500 or less; or of about 5000 or less; or

of about 3000 or less; or of about 2500 or less for δ receptors. In another embodiment, Compounds of the Invention exhibit a K_i (nM) of about 1000 or less; or of about 500 or less; or of about 350 or less; or of about 250 or less; or of about 100 or less; or of about 10 or less for δ receptors.

5 ***δ -Opioid Receptor Functional Assay Procedures:*** Functional [35 S]GTP γ S binding assays can be conducted as follows. δ -Opioid receptor membrane solution is prepared by sequentially adding final concentrations of 0.026 μ g/ μ l δ membrane protein (Perkin Elmer, Shelton, CT), 10 μ g/mL saponin, 3 μ M GDP and 0.20 nM [35 S]GTP γ S to binding buffer (100 mM NaCl, 10 mM MgCl₂, 20mM HEPES, pH 7.4) on ice. The prepared membrane solution
10 (190 μ l/well) is transferred to 96-shallow well polypropylene plates containing 10 μ l of 20x concentrated stock solutions of agonist prepared in DMSO. Plates are incubated for 30 min at a temperature of about 25°C with shaking. Reactions are terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, CT) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 μ l ice-cold binding
15 buffer (10 mM NaH₂PO₄, 10 mM Na₂HPO₄, pH 7.4). Filter plates are subsequently dried at 50°C for 1-2 hours. Fifty μ l/well scintillation cocktail (Perkin Elmer, Shelton, CT) is added and plates are counted in a Packard Top-count for 1 min/well.

δ -Opioid Receptor Functional Data: δ GTP EC₅₀ is the concentration of a compound providing 50% of the maximal response for the compound at a δ receptor. Certain
20 Compounds of the Invention exhibit a δ GTP EC₅₀ (nM) of about 20,000 or less; or about 10,000 or less. In certain embodiments, Compounds of the Invention exhibit a δ GTP EC₅₀ (nM) of about 3500 or less; or of about 1000 or less; or of about 500 or less; or of about 100 or less; or of about 90 or less; or of about 50 or less; or of about 25 or less; or of about 10 or less.

25 δ GTP E_{max} (%) is the maximal effect elicited by a compound relative to the effect elicited by met-enkephalin. Certain Compounds of the Invention exhibit a δ GTP E_{max} (%) of greater than about 1%; or of greater than about 5%; or of greater than about 10%. In one embodiment, Compounds of the Invention exhibit a δ GTP E_{max} (%) of greater than about 30%. In another embodiment, Compounds of the Invention exhibit a δ GTP E_{max} (%) of
30 greater than about 50%; or of greater than about 75%; or of greater than about 90%. In another embodiment, Compounds of the Invention exhibit a δ GTP E_{max} (%) of greater than about 100%.

ORL-1 Receptor Binding Assay Procedure: Membranes from recombinant HEK-293 cells expressing the human opioid receptor-like receptor (ORL-1) (Perkin Elmer, Shelton, CT) are prepared by lysing cells in ice-cold hypotonic buffer (2.5 mM MgCl₂, 50 mM HEPES, pH 7.4) (10 ml/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle.

Membranes are collected by centrifugation at 30,000 x g for 15 min at 4°C and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/ml. Protein concentrations are determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of the ORL-1 receptor membranes are stored at -80°C.

Radioligand binding assays (screening and dose-displacement) can use 0.1 nM [³H]-nociceptin (Perkin Elmer, Shelton, CT; 87.7 Ci/mmol) with 12 µg membrane protein in a final volume of 500 µl binding buffer (10 mM MgCl₂, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding is determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company).

All reactions are performed in 96-deep well polypropylene plates for 1 h at room temperature. Binding reactions are terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, CT) presoaked in 0.5% polyethylenimine (Sigma). Harvesting is performed using a 96-well tissue harvester (Perkin Elmer, Shelton, CT) followed by three filtration washes with 500 µl ice-cold binding buffer. Filter plates are subsequently dried at 50°C for 2-3 hours. Fifty µl/well scintillation cocktail (Perkin Elmer, Shelton, CT) are added and plates are counted in a Packard Top-Count for 1 min/well. The data from screening and dose-displacement experiments are analyzed using Microsoft Excel and the curve fitting functions in GraphPad PRISM™, v. 3.0 or higher, respectively, or an in-house function for one-site competition curve-fitting.

ORL-1 Receptor Binding Data: Certain Compounds of the Invention have a K_i (nM) of about 5000 or less. In one embodiment, certain Compounds of the Invention have a K_i (nM) of about 1000 or less. In one embodiment, certain Compounds of the Invention have a K_i (nM) of about 500 or less. In other embodiments, the Compounds of the Invention have a K_i (nM) of about 300 or less; or of about 100 or less; or of about 50 or less; or of about 20 or less. In yet other embodiments, the Compounds of the Invention will have a K_i (nM) of about 10 or less; or of about 1 or less; or of about 0.1 or less.

ORL-1 Receptor Functional Assay Procedure: Membranes from recombinant HEK-293 cells expressing the human opioid receptor-like (ORL-1) (Perkin Elmer, Shelton,

CT) can be prepared by lysing cells in ice-cold hypotonic buffer (2.5 mM Mg Cl₂, 50 mM HEPES, pH 7.4) (10 ml/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes are collected by centrifugation at 30,000 x g for 15 min at 4°C, and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/ml. Protein concentrations are determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of the ORL-1 receptor membranes are stored at -80°C.

Functional [³⁵S]GTPγS binding assays are conducted as follows. ORL-1 membrane solution is prepared by sequentially adding final concentrations of 0.026 μg/μl ORL-1 membrane protein, 10 μg/ml saponin, 3 μM GDP and 0.20 nM [³⁵S]GTPγS to binding buffer (100 mM NaCl, 10 mM MgCl₂, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 μl/well) is transferred to 96-shallow well polypropylene plates containing 10 μl of 20x concentrated stock solutions of agonist/nociceptin prepared in DMSO. Plates are incubated for 30 min at room temperature with shaking. Reactions are terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, CT) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 μl ice-cold binding buffer (10 mM NaH₂PO₄, 10 mM Na₂HPO₄, pH 7.4). Filter plates are subsequently dried at 50°C for 2-3 hours. Fifty μl/well scintillation cocktail (Perkin Elmer, Shelton, CT) is added and plates are counted in a Packard Top-Count for 1 min/well. Data are analyzed using the sigmoidal dose-response curve fitting functions in GraphPad PRISM v. 3.0 or higher, or an in-house function for non-linear, sigmoidal dose-response curve-fitting.

ORL-1 Receptor Functional Data: ORL-1 GTP EC₅₀ is the concentration of a compound providing 50% of the maximal response for the compound at an ORL-1 receptor. In certain embodiments, the Compounds of the Invention that have a high binding affinity (i.e. low K_i value) can have an ORL-1 GTP EC₅₀ (nM) of greater than about 10,000 (i.e. will not stimulate at therapeutic concentrations). In certain embodiments Compounds of the Invention can have an ORL-1 GTP EC₅₀ (nM) of about 20,000 or less. In one embodiment, the Compounds of the Invention can have an ORL-1 GTP EC₅₀ (nM) of about 10,000 or less; or of about 5000 or less; or of about 1000 or less. In still other embodiments, the Compounds of the Invention can have an ORL-1 GTP EC₅₀ (nM) of about 100 or less; or of about 10 or less; or of about 1 or less; or of about 0.1 or less.

ORL-1 GTP E_{max} % is the maximal effect elicited by a compound relative to the effect elicited by nociceptin, a standard ORL-1 agonist. In certain embodiments, Compounds of the Invention can have an ORL-1 GTP E_{max} of less than 10% (which, for the purposes of this

invention, is interpreted as having antagonist activity at ORL-1 receptors). Certain Compounds of the Invention can have an ORL-1 GTP E_{max} (%) of greater than 1%; or of greater than 5%; or of greater than 10%. In other embodiments the Compounds of the Invention can have an ORL-1 GTP E_{max} of greater than 20%; or of greater than 50%; or of greater than 75%; or of greater than 88%; or of greater than 100%.

In Vivo Assays for Pain

Test Animals: Each experiment uses rats weighing between 200-260 g at the start of the experiment. The rats are group-housed and have free access to food and water at all times, except prior to oral administration of a Compound of the Invention when food is removed for about 16 hours before dosing. A control group acts as a comparison to rats treated with a Compound of the Invention. The control group is administered the carrier for the Compound of the Invention. The volume of carrier administered to the control group is the same as the volume of carrier and Compound of the Invention administered to the test group.

Acute Pain: To assess the actions of a Compound of the Invention for the treatment or prevention of acute pain, the rat tail flick can be used. Rats are gently restrained by hand and the tail exposed to a focused beam of radiant heat at a point 5 cm from the tip using a tail flick unit (Model 7360, commercially available from Ugo Basile of Italy). Tail flick latencies are defined as the interval between the onset of the thermal stimulus and the flick of the tail. Animals not responding within 20 seconds are removed from the tail flick unit and assigned a withdrawal latency of 20 seconds. Tail flick latencies are measured immediately before (pre-treatment) and 1, 3, and 5 hours following administration of a Compound of the Invention. Data are expressed as tail flick latency(s) and the percentage of the maximal possible effect (% MPE), *i.e.*, 20 seconds, is calculated as follows:

$$\% \text{ MPE} = \frac{[(\text{post administration latency}) - (\text{pre-administration latency})]}{(20 \text{ s} - \text{pre-administration latency})} \times 100$$

The rat tail flick test is described in F.E. D'Amour *et al.*, "A Method for Determining Loss of Pain Sensation," *J. Pharmacol. Exp. Ther.* 72:74-79 (1941).

To assess the actions of a Compound of the Invention for the treatment or prevention of acute pain, the rat hot plate test can also be used. Rats are tested using a hot plate apparatus consisting of a clear plexiglass cylinder with a heated metal floor maintained at a temperature of 48-52 °C (Model 7280, commercially available from Ugo Basile of Italy). A rat is placed into the cylinder on the hot plate apparatus for a maximum duration of 30 s, or until it exhibits a nocifensive behavior (behavioral endpoint), at which time it is removed from the hot plate, and the response latency recorded. Hot plate latencies are measured immediately before (pre-treatment) and 1, 3, and 5 hours following administration of a Compound of the Invention.

The nocifensive behavioral endpoint is defined as any of the following: 1) paw withdrawal, either as a sustained lift or with shaking or licking; 2) alternating foot lifting; 3) escape or attempted escape from the testing device; or 4) vocalization. Data are expressed as response latency(s) and the percentage of the maximal possible effect is calculated as described above for the tail flick test. The hot plate test is described in G. Woolfe and A.D. MacDonald, *J. Pharmacol. Exp. Ther.* 80:300-307 (1944).

Inflammatory Pain: To assess the actions of a Compound of the Invention for the treatment or prevention of inflammatory pain, the Freund's complete adjuvant ("FCA") model of inflammatory pain can be used. FCA-induced inflammation of the rat hind paw is associated with the development of persistent inflammatory mechanical hyperalgesia and provides reliable prediction of the anti-hyperalgesic action of clinically useful analgesic drugs (L. Bartho *et al.*, "Involvement of Capsaicin-sensitive Neurones in Hyperalgesia and Enhanced Opioid Antinociception in Inflammation," *Naunyn-Schmiedeberg's Archives of Pharmacol.* 342:666-670 (1990)). The left hind paw of each animal is administered a 50 µL intraplantar injection of 50% FCA.

Prior to injection of FCA (baseline) and 24 hour post injection, the animal is assessed for response to noxious mechanical stimuli by determining the PWT, as described below. Rats are then administered a single injection of 1, 3, or 10 mg/kg of either a Compound of the Invention; 30mg/kg of a control drug selected from Celebrex, indomethacin or naproxen; or carrier. Responses to noxious mechanical stimuli are determined 1, 3, 5 and 24 hours post administration. Percentage reversal of hyperalgesia for each animal is defined as:

$$\% \text{ Reversal} = \frac{[(\text{post administration PWT}) - (\text{pre-administration PWT})]}{[(\text{baseline PWT}) - (\text{pre-administration PWT})]} \times 100$$

5 **Neuropathic Pain:** To assess the actions of a Compound of the Invention for the treatment or prevention of neuropathic pain, either the Seltzer model or the Chung model can be used.

In the Seltzer model, the partial sciatic nerve ligation model of neuropathic pain is used to produce neuropathic hyperalgesia in rats (Z. Seltzer *et al.*, "A Novel Behavioral Model of Neuropathic Pain Disorders Produced in Rats by Partial Sciatic Nerve Injury," *Pain* 43:205-218 (1990)). Partial ligation of the left sciatic nerve is performed under isoflurane/O₂ inhalation anaesthesia. Following induction of anesthesia, the left thigh of the rat is shaved and the sciatic nerve exposed at high thigh level through a small incision and is carefully cleared of surrounding connective tissues at a site near the trochanter just distal to the point at which the posterior biceps semitendinosus nerve branches off of the common sciatic nerve. A 7-0 silk suture is inserted into the nerve with a 3/8 curved, reversed-cutting mini-needle and tightly ligated so that the dorsal 1/3 to 1/2 of the nerve thickness is held within the ligature. The wound is closed with a single muscle suture (4-0 nylon (Vicryl)) and vetbond tissue glue. Following surgery, the wound area is dusted with antibiotic powder. Sham-treated rats undergo an identical surgical procedure except that the sciatic nerve is not manipulated. Following surgery, animals are weighed and placed on a warm pad until they recover from anesthesia. Animals are then returned to their home cages until behavioral testing begins. The animal is assessed for response to noxious mechanical stimuli by determining PWT, as described below, prior to surgery (baseline), then immediately prior to and 1, 3, and 5 hours after drug administration. Percentage reversal of neuropathic hyperalgesia is defined as:

$$\% \text{ Reversal} = \frac{[(\text{post administration PWT}) - (\text{pre-administration PWT})]}{[(\text{baseline PWT}) - (\text{pre-administration PWT})]} \times 100$$

In the Chung model, the spinal nerve ligation model of neuropathic pain is used to produce mechanical hyperalgesia, thermal hyperalgesia and tactile allodynia in rats. Surgery is performed under isoflurane/O₂ inhalation anaesthesia. Following induction of anaesthesia,

a 3 cm incision is made and the left paraspinal muscles are separated from the spinous process at the L₄ - S₂ levels. The L₆ transverse process is carefully removed with a pair of small rongeurs to identify visually the L₄ - L₆ spinal nerves. The left L₅ (or L₅ and L₆) spinal nerve(s) is isolated and tightly ligated with silk thread. A complete hemostasis is confirmed and the wound is sutured using non-absorbable sutures, such as nylon sutures or stainless steel staples. Sham-treated rats undergo an identical surgical procedure except that the spinal nerve(s) is not manipulated. Following surgery animals are weighed, administered a subcutaneous (s.c.) injection of saline or ringers lactate, the wound area is dusted with antibiotic powder and they are kept on a warm pad until they recover from the anesthesia. Animals are then returned to their home cages until behavioral testing begins. The animals are assessed for response to noxious mechanical stimuli by determining PWT, as described below, prior to surgery (baseline), then immediately prior to and 1, 3, and 5 hours after being administered a Compound of the Invention.

The animal can also be assessed for response to noxious thermal stimuli or for tactile allodynia, as described below. The Chung model for neuropathic pain is described in S.H. Kim, "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat," *Pain* 50(3):355-363 (1992).

Response to Mechanical Stimuli as an Assessment of Mechanical Hyperalgesia:

The paw pressure assay can be used to assess mechanical hyperalgesia. For this assay, hind paw withdrawal thresholds (PWT) to a noxious mechanical stimulus are determined using an analgesymeter (Model 7200, commercially available from Ugo Basile of Italy) as described in C. Stein, "Unilateral Inflammation of the Hindpaw in Rats as a Model of Prolonged Noxious Stimulation: Alterations in Behavior and Nociceptive Thresholds," *Pharmacol. Biochem. and Behavior* 31:451-455 (1988). The rat is gently restrained, its hindpaw is placed on a small round platform, and punctate pressure is applied to the dorsal surface of the hindpaw in a graded manner. The maximum weight that is applied to the hind paw is set at 250 g and the end point is taken as complete withdrawal of the paw. PWT is determined once for each rat at each time point and either only the affected (ipsilateral; same side as the injury) rear paw is tested, or both the ipsilateral and contralateral (non-injured; opposite to the injury) rear paw are tested.

Response to Thermal Stimuli as an Assessment of Thermal Hyperalgesia: The plantar test can be used to assess thermal hyperalgesia. For this test, hind paw withdrawal latencies to a noxious thermal stimulus applied to the plantar surface of the hindpaw are

determined using a plantar test apparatus (commercially available from Ugo Basile of Italy) following the technique described by K. Hargreaves *et al.*, "A New and Sensitive Method for Measuring Thermal Nociception in Cutaneous Hyperalgesia," *Pain* 32(1):77-88 (1988). The maximum exposure time is set at 32 seconds to avoid tissue damage and any directed paw withdrawal from the heat source is taken as the end point. Three latencies are determined at each time point and averaged. Either only the affected (ipsilateral) paw is tested, or both the ipsilateral and contralateral (non-injured) paw are tested.

Assessment of Tactile Allodynia: To assess tactile allodynia, rats are placed in clear, plexiglass compartments with a wire mesh floor and allowed to habituate for a period of at least 15 minutes. After habituation, a series of von Frey monofilaments are presented to the plantar surface of the affected (ipsilateral) foot of each rat. The series of von Frey monofilaments consists of six monofilaments of increasing diameter, with the smallest diameter fiber presented first. Five trials are conducted with each filament with each trial separated by approximately 2 minutes. Each presentation lasts for a period of 4-8 seconds or until a nociceptive withdrawal behavior is observed. Flinching, paw withdrawal or licking of the paw are considered nociceptive behavioral responses.

Assessment of Respiratory Depression: To assess respiratory depression, rats can be prepared by implanting a femoral artery cannula via which blood samples are taken. Blood samples are taken prior to drug administration, then 1, 3, 5 and 24 hours post-treatment. Blood samples are processed using an arterial blood gas analyzer (*e.g.*, IDEXX VetStat with Respiratory/Blood Gas test cartridges). Comparable devices are a standard tool for blood gas analysis (*e.g.*, D. Torbati *et al.*, *Intensive Care Med.* (26): 585-591 (2000)).

Assessment of Gastric Motility: Animals are treated with vehicle, reference compound or test article by oral gavage at a volume of 10 mL/kg. At one hour post-dose, all animals are treated with charcoal meal solution (5% non-activated charcoal powder in a solution of 1 % carboxymethylcellulose in water) at a volume of 10 mL/kg. At two hours post-dose (one hour post-charcoal), animals are sacrificed by carbon dioxide inhalation or isoflurane overdose and the transit of charcoal meal identified. The stomach and small intestine are removed carefully and each placed on a saline-soaked absorbent surface. The distance between the pylorus and the furthest progression of charcoal meal is measured and compared to the distance between the pylorus and the ileocecal junction. The charcoal meal transit is expressed as a percentage of small intestinal length traveled.

Pharmaceutical Compositions

Due to their activity, the Compounds of the Invention are advantageously useful in human and veterinary medicine. As described above, the Compounds of the Invention are useful for treating or preventing a Condition in a patient in need thereof. The Compounds of the Invention can be administered to any patient requiring modulation of the opioid receptors. The term "patient" as used herein refers to any animal that may experience the beneficial effects of a Compound of the Invention. Foremost such animals are mammals, *e.g.*, humans and companion animals, although the invention is not intended to be so limited.

When administered to a patient, a Compound of the Invention can be administered as a component of a composition that comprises a pharmaceutically acceptable carrier or excipient. A Compound of the Invention can be administered by any appropriate route, as determined by the medical practitioner. Methods of administration may include intradermal, intramuscular, intraperitoneal, parenteral, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, buccal, intracerebral, intravaginal, transdermal, transmucosal, rectal, by inhalation, or topical (particularly to the ears, nose, eyes, or skin). Delivery can be either local or systemic. In certain embodiments, administration will result in the release of a Compound of the Invention into the bloodstream.

Pharmaceutical compositions of the invention can take the form of solutions, suspensions, emulsions, tablets, pills, pellets, powders, multi-particulates, capsules, capsules containing liquids, capsules containing powders, capsules containing multi-particulates, lozenges, sustained-release formulations, suppositories, transdermal patches, transmucosal films, sub-lingual tablets or tabs, aerosols, sprays, or any other form suitable for use. In one embodiment, the composition is in the form of a tablet. In another embodiment, the composition is in the form of a capsule (*see, e.g.*, U.S. Patent No. 5,698,155). Other examples of suitable pharmaceutical excipients are described in *Remington's Pharmaceutical Sciences* 1447-1676 (Alfonso R. Gennaro ed., 19th ed. 1995), incorporated herein by reference.

Pharmaceutical compositions of the invention preferably comprise a suitable amount of a pharmaceutically acceptable excipient so as to provide the form for proper administration to the patient. Such a pharmaceutical excipient can be a diluent, suspending agent, solubilizer, binder, disintegrant, preservative, coloring agent, lubricant, and the like. The pharmaceutical excipient can be a liquid, such as water or an oil, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil,

sesame oil, and the like. The pharmaceutical excipient can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used. In one embodiment, the pharmaceutically acceptable excipient is sterile when administered to a patient. Water is a particularly useful excipient when a Compound of the Invention is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, particularly for injectable solutions.

Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like. The invention compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. Specific examples of pharmaceutically acceptable carriers and excipients that can be used to formulate oral dosage forms are described in the *Handbook of Pharmaceutical Excipients*, American Pharmaceutical Association (1986).

In certain embodiments, the Compounds of the Invention are formulated for oral administration. A Compound of the Invention to be orally delivered can be in the form of tablets, capsules, gencaps, caplets, lozenges, aqueous or oily solutions, suspensions, granules, powders, emulsions, syrups, or elixirs, for example. When a Compound of the Invention is incorporated into oral tablets, such tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated, multiply compressed or multiply layered.

An orally administered Compound of the Invention can contain one or more additional agents such as, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, and stabilizers, to provide stable, pharmaceutically palatable dosage forms. Techniques and compositions for making solid oral dosage forms are described in *Pharmaceutical Dosage Forms: Tablets* (Lieberman, Lachman and Schwartz, eds., 2nd ed.) published by Marcel Dekker, Inc. Techniques and compositions for making tablets (compressed and molded), capsules (hard and soft gelatin) and pills are also described in *Remington's Pharmaceutical Sciences* 1553-1593 (Arthur Osol, ed., 16th ed., Mack Publishing, Easton, PA 1980). Liquid oral dosage forms include aqueous and nonaqueous solutions, emulsions, suspensions, and solutions and/or suspensions reconstituted from non-effervescent granules, optionally containing one or more suitable solvents, preservatives,

emulsifying agents, suspending agents, diluents, sweeteners, coloring agents, flavoring agents, and the like. Techniques and compositions for making liquid oral dosage forms are described in *Pharmaceutical Dosage Forms: Disperse Systems*, (Lieberman, Rieger and Banker, eds.) published by Marcel Dekker, Inc.

5 When a Compound of the Invention is formulated for parenteral administration by injection (*e.g.*, continuous infusion or bolus injection), the formulation can be in the form of a suspension, solution, or emulsion in an oily or aqueous vehicle, and such formulations can further comprise pharmaceutically necessary additives such as one or more stabilizing agents, suspending agents, dispersing agents, and the like. When a Compound of the Invention is to
10 be injected parenterally, it can be, *e.g.*, in the form of an isotonic sterile solution. A

Compound of the Invention can also be in the form of a powder for reconstitution as an injectable formulation.

In certain embodiments, a Compound of the Invention is formulated into a pharmaceutical composition for intravenous administration. Typically, such compositions
15 comprise sterile isotonic aqueous buffer. Where necessary, the compositions can also include a solubilizing agent. A Compound of the Invention for intravenous administration can optionally include a local anesthetic such as benzocaine or prilocaine to lessen pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a
20 hermetically sealed container such as an ampule or sachette indicating the quantity of active agent. Where a Compound of the Invention is to be administered by infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where a Compound of the Invention is administered by injection, an ampule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior
25 to administration.

When a Compound of the Invention is to be administered by inhalation, it can be formulated into a dry aerosol, or an aqueous or partially aqueous solution.

In another embodiment, a Compound of the Invention can be delivered in a vesicle, in particular a liposome (*see* Langer, *Science* 249:1527-1533 (1990); and Treat *et al.*, *Liposomes in the Therapy of Infectious Disease and Cancer* 317-327 and 353-365 (1989)).
30

In certain embodiments, a Compound of the Invention is administered locally. This can be achieved, for example, by local infusion during surgery, topical application, *e.g.*, in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by

means of a suppository or enema, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.

In certain embodiments, a Compound of the Invention can be delivered in an immediate release form. In other embodiments, a Compound of the Invention can be delivered in a controlled-release system or sustained-release system. Controlled- or sustained-release pharmaceutical compositions can have a common goal of improving drug therapy over the results achieved by their non-controlled or non-sustained-release counterparts. In one embodiment, a controlled- or sustained-release composition comprises a minimal amount of a Compound of the Invention to treat or prevent the Condition (or a symptom thereof) in a minimum amount of time. Advantages of controlled- or sustained-release compositions include extended activity of the drug, reduced dosage frequency, and increased compliance. In addition, controlled- or sustained-release compositions can favorably affect the time of onset of action or other characteristics, such as blood levels of the Compound of the Invention, and can thus reduce the occurrence of adverse side effects.

Controlled- or sustained-release compositions can initially immediately release an amount of a Compound of the Invention that promptly produces the desired therapeutic or prophylactic effect, and gradually and continually release other amounts of the Compound of the Invention to maintain a level of therapeutic or prophylactic effect over an extended period of time. To maintain a constant level of the Compound of the Invention in the body, the Compound of the Invention can be released from the dosage form at a rate that will replace the amount of Compound of the Invention being metabolized and excreted from the body. Controlled- or sustained-release of an active ingredient can be stimulated by various conditions, including but not limited to, changes in pH, changes in temperature, concentration or availability of enzymes, concentration or availability of water, or other physiological conditions or compounds.

Controlled-release and sustained-release means for use according to the present invention may be selected from those known in the art. Examples include, but are not limited to, those described in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; and 5,733,566, each of which is incorporated herein by reference. Such dosage forms can be used to provide controlled- or sustained-release of one or more active ingredients using, for example, hydroxypropylmethyl cellulose, other polymer matrices, gels, permeable

membranes, osmotic systems, multilayer coatings, microparticles, multiparticulates, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled- or sustained-release formulations known in the art, including those described herein, can be readily selected for use with the active ingredients of the invention in view of this disclosure. See also Goodson, "Dental Applications" (pp. 115-138) in *Medical Applications of Controlled Release, Vol. 2, Applications and Evaluation*, R.S. Langer and D.L. Wise eds., CRC Press (1984). Other controlled- or sustained-release systems that are discussed in the review by Langer, *Science* 249:1527-1533 (1990) can be selected for use according to the present invention.

In one embodiment, a pump can be used (Langer, *Science* 249:1527-1533 (1990); Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald *et al.*, *Surgery* 88:507 (1980); and Saudek *et al.*, *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (*see Medical Applications of Controlled Release* (Langer and Wise eds., 1974); *Controlled Drug Bioavailability, Drug Product Design and Performance* (Smolen and Ball eds., 1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); Levy *et al.*, *Science* 228:190 (1985); During *et al.*, *Ann. Neurol.* 25:351 (1989); and Howard *et al.*, *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled- or sustained-release system can be placed in proximity of a target of a Compound of the Invention, *e.g.*, the spinal column, brain, or gastrointestinal tract, thus requiring only a fraction of the systemic dose.

When in tablet or pill form, a pharmaceutical composition of the invention can be coated to delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active driving compound are also suitable for orally administered compositions. In these latter platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time-delay material such as glycerol monostearate or glycerol stearate can also be used. Oral compositions can include standard excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. In one embodiment, the excipients are of pharmaceutical grade.

Pharmaceutical compositions of the invention include single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled- or sustained-release.

5 The amount of the Compound of the Invention that is effective for the treatment or prevention of a condition can be determined by standard clinical techniques. In addition, *in vitro* and/or *in vivo* assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed will also depend on, *e.g.*, the route of administration and the extent of the Condition to be treated, and can be decided according to the judgment of a practitioner and/or each patient's circumstances. Variations in dosing may occur depending
10 upon typical factors such as the weight, age, gender and physical condition (*e.g.*, hepatic and renal function) of the patient being treated, the affliction to be treated, the severity of the symptoms, the frequency of the dosage interval, the presence of any deleterious side-effects, and the particular compound utilized, among other things.

Suitable effective dosage amounts can range from about 0.01mg/kg of body weight to
15 about 3000 mg/kg of body weight of the patient per day, although they are typically from about 0.01mg/kg of body weight to about 2500 mg/kg of body weight of the patient per day or from about 0.01mg/kg of body weight to about 1000 mg/kg of body weight of the patient per day. In one embodiment, the effective dosage amount is about 100 mg/kg of body weight of the patient per day or less. In another embodiment, the effective dosage amount ranges
20 from about 0.01mg/kg of body weight to about 100 mg/kg of body weight of the patient per day of a Compound of the Invention, in another embodiment, about 0.02 mg/kg of body weight to about 50 mg/kg of body weight of the patient per day, and in another embodiment, about 0.025 mg/kg of body weight to about 20 mg/kg of body weight of the patient per day.

Administration can be as a single dose or as a divided dose. In one embodiment, an effective
25 dosage amount is administered about every 24 hours until the Condition is abated. In another embodiment, an effective dosage amount is administered about every 12 hours until the Condition is abated. In another embodiment, an effective dosage amount is administered about every 8 hours until the Condition is abated. In another embodiment, an effective dosage amount is administered about every 6 hours until the Condition is abated. In another
30 embodiment, an effective dosage amount is administered about every 4 hours until the Condition is abated. The effective dosage amounts described herein refer to total amounts administered; that is, if more than one Compound of the Invention is administered, the effective dosage amounts correspond to the total amount administered.

Where a cell capable of expressing the μ -opioid receptors is contacted with a Compound of the Invention *in vitro*, the amount effective for inhibiting or activating the μ -opioid receptors function in a cell can typically range from about 10^{-12} mol/L to about 10^{-4} mol/L, or from about 10^{-12} mol/L to about 10^{-5} mol/L, or from about 10^{-12} mol/L to about 10^{-6} mol/L, or from about 10^{-12} mol/L to about 10^{-9} mol/L of a solution or suspension of the Compound of the Invention in a pharmaceutically acceptable carrier or excipient. In one embodiment, the volume of solution or suspension comprising the Compound of the Invention can be from about 0.01 μ L to about 1 mL. In another embodiment, the volume of solution or suspension can be about 200 μ L.

Where a cell capable of expressing the δ -opioid receptors is contacted with a Compound of the Invention *in vitro*, the amount effective for inhibiting or activating the δ -opioid receptors function in a cell can typically range from about 10^{-12} mol/L to about 10^{-4} mol/L, or from about 10^{-12} mol/L to about 10^{-5} mol/L, or from about 10^{-12} mol/L to about 10^{-6} mol/L, or from about 10^{-12} mol/L to about 10^{-9} mol/L of a solution or suspension of the Compound of the Invention in a pharmaceutically acceptable carrier or excipient. In one embodiment, the volume of solution or suspension comprising the Compound of the Invention can be from about 0.01 μ L to about 1 mL. In another embodiment, the volume of solution or suspension can be about 200 μ L.

Where a cell capable of expressing the κ -opioid receptors is contacted with a Compound of the Invention *in vitro*, the amount effective for inhibiting or activating the κ -opioid receptors function in a cell can typically range from about 10^{-12} mol/L to about 10^{-4} mol/L, or from about 10^{-12} mol/L to about 10^{-5} mol/L, or from about 10^{-12} mol/L to about 10^{-6} mol/L, or from about 10^{-12} mol/L to about 10^{-9} mol/L of a solution or suspension of the Compound of the Invention in a pharmaceutically acceptable carrier or excipient. In one embodiment, the volume of solution or suspension comprising the Compound of the Invention can be from about 0.01 μ L to about 1 mL. In another embodiment, the volume of solution or suspension can be about 200 μ L.

Where a cell capable of expressing the ORL-1 receptor is contacted with a Compound of the Invention *in vitro*, the amount effective for inhibiting or activating the ORL-1 receptor function in a cell can typically range from about 10^{-12} mol/L to about 10^{-4} mol/L, or from about 10^{-12} mol/L to about 10^{-5} mol/L, or from about 10^{-12} mol/L to about 10^{-6} mol/L, or from about 10^{-12} mol/L to about 10^{-9} mol/L of a solution or suspension of the compound in a

pharmaceutically acceptable carrier or excipient. In one embodiment, the volume of solution or suspension comprising the Compound of the Invention can be from about 0.01 μ L to about 1mL. In another embodiment, the volume of solution or suspension can be about 200 μ L.

Compounds of the Invention can be assayed *in vitro* or *in vivo* for the desired
5 therapeutic or prophylactic activity prior to use in humans. Animal model systems can be used to demonstrate safety and efficacy. Certain Compounds of the Invention are expected to have an ED₅₀ for treating inflammatory pain ranging from about 0.5 mg/kg to about 20 mg/kg. Certain Compounds of the Invention are expected to produce significant analgesia and/or anti-hyperalgesia at doses that do not induce respiratory depression. In contrast,
10 oxygen tension, oxygen saturation and pH are significantly decreased, while carbon dioxide is significantly increased, in blood samples from rats given effective doses of conventional opioids, such as morphine.

According to the present invention, methods for treating or preventing a Condition in a patient in need thereof can further comprise co-administering to the patient an effective
15 amount of a second therapeutic agent in addition to a Compound of the Invention (*i.e.*, a first therapeutic agent). An effective amount of the second therapeutic agent can be known or determinable by a medical practitioner in view of this disclosure and published clinical studies. In one embodiment of the invention, where a second therapeutic agent is administered to a patient for treatment of a Condition (*e.g.*, pain), the minimal effective
20 amount of the Compound of the Invention (*i.e.*, the first therapeutic agent) will be less than its minimal effective amount would be in circumstances where the second therapeutic agent is not administered. In this embodiment, the Compound of the Invention and the second therapeutic agent can act either additively or synergistically to treat or prevent a Condition.

Alternatively, the second therapeutic agent may be used to treat or prevent a disorder
25 that is different from the Condition for which the first therapeutic agent is being administered, and which disorder may or may not be a Condition as defined hereinabove. In one embodiment, a Compound of the Invention is administered concurrently with a second therapeutic agent as a single composition comprising an effective amount of a Compound of the Invention and an effective amount of the second therapeutic agent.

30 Alternatively, a composition comprising an effective amount of a Compound of the Invention and a second composition comprising an effective amount of the second therapeutic agent are concurrently administered. In another embodiment, an effective amount of a Compound of the Invention is administered prior or subsequent to administration of an

effective amount of the second therapeutic agent. In this embodiment, the Compound of the Invention is administered while the second therapeutic agent exerts its therapeutic effect, or the second therapeutic agent is administered while the Compound of the Invention exerts its therapeutic effect for treating or preventing a Condition.

5 The second therapeutic agent can be, but is not limited to, an opioid agonist, a non-opioid analgesic, a non-steroidal anti-inflammatory agent, an antimigraine agent, a Cox-IA inhibitor, a 5-lipoxygenase inhibitor, an anti-emetic, a β -adrenergic blocker, an anticonvulsant, an antidepressant, a Ca^{2+} -channel blocker, an anti-cancer agent, an agent for treating or preventing UI, an agent for treating or preventing anxiety, an agent for treating or preventing a memory disorder, an agent for treating or preventing obesity, an agent for treating or preventing constipation, an agent for treating or preventing cough, an agent for treating or preventing diarrhea, an agent for treating or preventing high blood pressure, an agent for treating or preventing epilepsy, an agent for treating or preventing anorexia/cachexia, an agent for treating or preventing drug abuse, an agent for treating or preventing an ulcer, an agent for treating or preventing IBD, an agent for treating or preventing IBS, an agent for treating or preventing addictive disorder, an agent for treating or preventing Parkinson's disease and parkinsonism, an agent for treating or preventing a stroke, an agent for treating or preventing a seizure, an agent for treating or preventing a pruritic condition, an agent for treating or preventing psychosis, an agent for treating or preventing Huntington's chorea, an agent for treating or preventing ALS, an agent for treating or preventing a cognitive disorder, an agent for treating or preventing a migraine, an agent for treating, preventing or inhibiting vomiting, an agent for treating or preventing dyskinesia, an agent for treating or preventing depression, or any mixture thereof.

25 A composition of the invention is prepared by a method comprising admixing a Compound of the Invention with a pharmaceutically acceptable carrier or excipient. Admixing can be accomplished using methods known for admixing a compound (or derivative) and a pharmaceutically acceptable carrier or excipient. In one embodiment, the Compound of the Invention is present in the composition in an effective amount.

30 The present invention also relates to a kit, comprising a sterile container containing an effective amount of a Compound of the Invention and instructions for therapeutic use.


The following examples are illustrative, but not limiting, of the compounds, compositions and methods of the present invention. Suitable modifications and adaptations of the variety of conditions and parameters normally encountered in clinical therapy and which are obvious

to those skilled in the art in view of this disclosure are within the spirit and scope of the invention.

EXAMPLES

EXAMPLE 1

5 **Methyl (6R,6aS,12aR)-6a-hydroxy-2-methoxy-15-methyl-10-oxo-6,6a,7,10,11,12-hexahydro-5H-6,12a-(epiminoethano)naphtho[2,1-g]quinoline-9-carboxylate (2)**




10 The starting **Compound 1** can be prepared as described in, for example, Hupp C. D., *et al.*, *Tetrahedron Letters* 51:2359-2361 (2010).

To a suspension of **Compound 1** (10.01 g, 35.1 mmol) in Et₂O (140 mL) was added methyl formate (4.8 mL, 78 mmol) and NaOEt (7.93 g, 117 mmol). The reaction mixture was stirred overnight then diluted with 25 mL saturated NH₄Cl solution. The resulting solids were isolated, diluted with 50 mL brine and 50 mL water, then extracted (6x) with 100 mL
15 3:1 CHCl₃ / EtOH. The aqueous portion was then saturated with solid NaCl and extracted (3x) with 100 mL 3:1 CHCl₃ / EtOH. The combined organic extracts were dried over MgSO₄, filtered and evaporated in vacuo to give the crude enol ketone intermediate **Compound 1a**.

To the crude **Compound 1a** was added MeCN (170 mL), methyl cyanoacetate (4.4
20 mL, 50 mmol) and piperidine (3.3 mL, 33 mmol). The reaction mixture was heated in a sealed vessel at 80 °C overnight. The reaction mixture was evaporated in vacuo and the residue purified by flash chromatography (SiO₂, 0-18% (10% NH₄OH in MeOH) in DCM). The product fractions were combined and evaporated in vacuo to give a solid. This solid was triturated with 25 mL MeOH, filtered, and rinsed once with 10 mL MeOH. The resulting
25 material was dried under reduced pressure to give **Compound 2** as a yellow powder (4.141 g). Yield 30%. LC/MS, *m/z* = 411.2 [M + H]⁺ (Calc: 410).

EXAMPLE 2


15-(tert-Butyl) 9-methyl (6R,6aS,12aR)-6a-hydroxy-2-methoxy-10-oxo-6,6a,7,10,11,12-hexahydro-5H-6,12a-(epiminoethano)naphtho[2,1-g]quinoline-9,15-dicarboxylate (3)

3

Compound **3** was prepared according to the procedure described in Example 1 from tert-butyl(4bS,8aR,9R)-3-methoxy-6-oxo-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthrene-11-carboxylate rather than (4bR,8aS,9R)-11-methyl-8a-hydroxy-3-methoxy-8,8a,9,10-tetrahydro-5H-9,4b-(epiminoethano)phenanthren-6(7H)-one (**Compound 1**).

¹H NMR δ_H (400 MHz, CDCl₃): 7.82 (s, 1H), 6.99 (d, *J*=8.42 Hz, 1H), 6.79 (d, *J*=2.37 Hz, 1H), 6.68 (dd, *J*=2.53, 8.42 Hz, 1H), 4.57 (br. s., 1H), 3.75-3.96 (m, 4H), 3.55 (s, 3H), 3.32-3.45 (m, 2H), 3.14-3.29 (m, 1H), 2.96 (d, *J*=18.60 Hz, 1H), 2.67-2.80 (m, 2H), 2.51-2.68 (m, 2H), 2.17 (br. s., 1H), 1.50 (s, 9H), 1.24-1.41 (m, 1H); LC/MS, *m/z* = 498 [M + H]⁺ (Calc: 497).

EXAMPLE 3

Methyl (6R,6aS,12aR)-6a-hydroxy-2-methoxy-10-oxo-6,6a,7,10,11,12-hexahydro-5H-6,12a-(epiminoethano)naphtho[2,1-g]quinoline-9-carboxylate (4)

3

4

Into a sealed tube containing **Compound 3** (0.030 g, 0.060 mmol) dissolved in DCM (0.24 ml) was added 4N HCl in Dioxane (0.05 ml, 0.20 mmol). The mixture was stirred for 16 h at RT. Mixing was stopped and the reaction was allowed to separate into layers. The clear DCM layer was cut away leaving a pale yellow insoluble residue. This material was


trituated with cold DCM and dried under reduced pressure to give the HCl salt of **Compound 4** as a light yellow solid (16.5 mg). Yield 67%.

^1H NMR δ_{H} (400 MHz, CD_3OD): 7.94 (s, 1H), 7.19 (d, $J=8.25$ Hz, 1H), 6.80-6.90 (m, 2H), 3.78-3.86 (m, 4H), 3.75 (s, 3H), 3.60 (dd, $J=7.12, 19.50$ Hz, 1H), 3.35-3.40 (m, 1H), 3.22 (d, $J=19.48$ Hz, 1H), 3.10-3.19 (m, 2H), 2.87 (dt, $J=3.63, 13.42$ Hz, 1H), 2.70-2.81 (m, 1H), 2.59-2.68 (m, 1H), 2.50 (dt, $J=5.06, 13.73$ Hz, 1H), 1.55 (dd, $J=2.50, 13.73$ Hz, 1H); LC/MS, $m/z = 397$ $[\text{M} + \text{H}]^+$ (Calc: 396).

EXAMPLE 4

(6*R*,6*aS*,12*aR*)-6*a*-hydroxy-2-methoxy-10-oxo-6,6*a*,7,10,11,12-hexahydro-5*H*-6,12*a*-(epiminoethano)naphtho[2,1-*g*]quinoline-9-carboxamide (**5**)

(6*R*,6*aS*,12*aR*)-6*a*-hydroxy-2-methoxy-10-oxo-6,6*a*,7,10,11,12-hexahydro-5*H*-6,12*a*-(epiminoethano)naphtho[2,1-*g*]quinoline-9-carboxamide (**6**)




(a) **Compound 3** (0.100 g, 0.101 mmol), dissolved in 7N NH_3 in MeOH (1.17 ml, 8.16 mmol), was stirred in a sealed tube for 2 days. The reaction mixture was concentrated to dryness to afford a quantitative yield of crude **Compound 5**. LC/MS, $m/z = 482.2$ $[\text{M} + \text{H}]^+$ (Calc: 481.5).

(b) Into a pressure tube containing a solution of crude **Compound 5** (0.100 g, 0.208 mmol) in DCM (0.4 ml) at 0 °C was added a 1M solution of boron tribromide in DCM (1.25 ml, 1.25 mmol). The ice bath was removed and the mixture was stirred at room temperature for 35 min. The mixture was neutralized with saturated aqueous NaHCO_3 . The aqueous layer was cut away, evaporated in vacuo, re-dissolved in 30 ml of 1:1 MeOH:DCM, and adsorbed onto silica gel. The adsorbed material was purified by flash chromatography (SiO_2 , 0-35% (15% Aq NH_4OH in MeOH) in DCM) to give the title **Compound 6** as a pale yellow solid (0.020 g). Yield 54%.

¹H NMR δ_H (400 MHz, DMSO-*d*₆): 9.10 (br. s., 1H), 9.05 (d, *J*=4.62 Hz, 1H), 7.80-7.91 (m, 1H), 7.37 (d, *J*=4.51 Hz, 1H), 6.84-6.96 (m, 1H), 6.46-6.60 (m, 2H), 4.84 (br. s., 1H), 4.09 (br. s., 1H), 3.22-3.31 (m, 2H), 3.17 (s, 1H), 2.99-3.10 (m, 1H), 2.78-2.99 (m, 3H), 2.52-2.60 (m, 1H), 2.25-2.48 (m, 3H), 1.98 (dt, *J*=5.03, 12.56 Hz, 1H), 0.98 (d, *J*=11.55 Hz, 1H);
 5 LC/MS, *m/z* = 368 [M + H]⁺ (Calc: 367).

EXAMPLE 5

Methyl (6*R*,6*aS*,12*aR*)-11-ethyl-6*a*-hydroxy-2-methoxy-15-methyl-10-oxo-6,6*a*,7,10,11,12-hexahydro-5*H*-6,12*a*-(epiminoethano)naphtho[2,1-*g*]quinoline-9-carboxylate (7)




To a mixture of **Compound 2** (1.00 g, 2.45 mmol) in MeCN (25 mL) was added K₂CO₃ (0.69 g, 4.91 mmol) and ethyl iodide (0.22 mL, 2.74 mmol). The reaction was heated
 15 at 50 °C overnight then at 80 °C for 4 days. After cooling, the reaction mixture was filtered to remove the insoluble materials and the filtrate evaporated in vacuo. The residue was purified by flash chromatography (SiO₂, 0-15% (10% NH₄OH in MeOH) in DCM) to give **Compound 7** as a tan powder (0.21 g). Yield 19%.

¹H NMR δ_H (400 MHz, DMSO-*d*₆): 7.57 (s, 1H), 7.07 (d, *J*=8.4 Hz, 1H), 6.80 (d, *J*=2.5 Hz, 1H), 6.70 (dd, *J*=8.4, 2.5 Hz, 1H), 4.63 (d, *J*=1.3 Hz, 1H), 4.35-4.24 (m, 1H), 4.18-4.07 (m, 1H), 3.66 (s, 3H), 3.64 (s, 3H), 3.58-3.49 (m, 1H), 3.19-3.08 (m, 1H), 3.00-2.91 (m, 1H), 2.88-2.78 (m, 2H), 2.57 (d, *J*=17.1 Hz, 1H), 2.41-2.29 (m, 5H), 2.17-2.06 (m, 1H), 2.03-1.94 (m, 1H), 1.35-1.22 (m, 4H); LC/MS, *m/z* = 439.0 [M + H]⁺ (Calc: 438.5).

EXAMPLE 6

(6*R*,6*aR*,12*aS*)-2-methoxy-15-methyl-10-oxo-6,6*a*,7,10,11,12-hexahydro-5*H*-6,12*a*-(epiminoethano)naphtho[2,1-*g*]quinoline-9-carboxylic acid (8)


(6*R*,6*aS*,12*aR*)-11-ethyl-6*a*-hydroxy-2-methoxy-15-methyl-10-oxo-6,6*a*,7,10,11,12-hexahydro-5*H*-6,12*a*-(epiminoethano)naphtho[2,1-*g*]quinoline-9-carboxylic acid (9)



To a mixture of **Compound 2** (4.14 g, 10.50 mmol) in THF (50 mL) and water (10 mL) was added LiOH•H₂O (0.67 g, 16.0 mmol). The reaction was heated at 50 °C for 3 days then evaporated *in vacuo*. The residue was diluted with 25 mL water and treated with 1N aqueous HCl (16.0 mL, 16.0 mmol). The solids were isolated by filtration, rinsed once with 10 mL water, and dried to give **Compound 8** as a light tan powder (3.29 g). Yield 82%.

¹H NMR δ_H (400 MHz, DMSO-*d*₆): 15.40 (br. s, 1H), 12.73 (br. s, 1H), 7.82 (s, 1H), 7.06 (d, J=8.4 Hz, 1H), 6.74-6.66 (m, 2H), 3.64 (s, 3H), 3.46 (d, J=17.9 Hz, 1H), 3.12-3.05 (m, 1H), 3.01 (d, J=18.8 Hz, 1H), 2.85-2.71 (m, 2H), 2.62 (dd, J=15.8, 5.3 Hz, 1H), 2.50-2.42 (m, 1H, overlap with DMSO), 2.38 (s, 3H), 2.31-2.14 (m, 2H), 2.13-2.00 (m, 1H), 1.84 (td, J=12.6, 4.6 Hz, 1H), 1.47 (d, J=12.6 Hz, 1H); LC/MS, *m/z* = 381.1 [M + H]⁺ (Calc: 380.4).

In a similar manner, the **Compound 9** was prepared starting from **Compound 7**:




LC/MS, *m/z* = 425.0 [M + H]⁺ (Calc: 424.5).

EXAMPLE 7

(6*R*,6*aR*,12*aS*)-*N*-benzyl-2-methoxy-15-methyl-10-oxo-6,6*a*,7,10,11,12-hexahydro-5*H*-6,12*a*-(epiminoethano)naphtho[2,1-*g*]quinoline-9-carboxamide (**10**)

(6*R*,6*aR*,12*aS*)-*N*-benzyl-2-hydroxy-15-methyl-10-oxo-6,6*a*,7,10,11,12-hexahydro-5*H*-6,12*a*-(epiminoethano)naphtho[2,1-*g*]quinoline-9-carboxamide (**11**)



(a) To a mixture of **Compound 8** (0.20 g, 0.528 mmol) in DMF (5 mL) was added DIPEA (0.14 mL, 0.80 mmol) and HATU (0.26 g, 0.64 mmol). After ~20-25 minutes, benzylamine (0.07 mL, 0.63 mmol) was added. After 3 days, the reaction mixture was evaporated *in vacuo* and the residue was purified by flash chromatography (SiO₂, 0-25% (10% NH₄OH in MeOH) in DCM) to give **Compound 10** as a tan solid (0.18 g). Yield 73%. LC/MS: m/z = 470.2 [M + H]⁺ (Calc: 469.6).

(b) To a mixture of **Compound 10** (0.18 g, 0.39 mmol) in DCM (15 mL) was added 1M BBr₃ in DCM (1.6 mL, 1.6 mmol). After 4 h, the reaction was quenched with 1.5 mL 5M concentrated NH₄OH in MeOH. The mixture was evaporated *in vacuo* and the residue was purified by flash chromatography (SiO₂, 0-25% (10% NH₄OH in MeOH) in DCM). The product fractions were combined, evaporated *in vacuo*, and the residue partitioned between 5 mL DCM and 1 mL 1N NaOH. The residue was purified by reverse-phase chromatography (C18, 0-60% 0.1% TFA in ACN/0.1% TFA in water). The product fractions were lyophilized to give the TFA salt of **Compound 11** as a cream-colored powder (0.041 g). Yield 19%.

¹H NMR δ_H (400 MHz, D₂O): 7.92 (s, 1H), 7.35-7.18 (m, 5H), 7.08 (d, J=8.5 Hz, 1H), 6.83 (d, J=2.0 Hz, 1H), 6.71 (dd, J=8.3, 2.1 Hz, 1H), 4.56-4.40 (m, 2H), 3.88 (br. s., 1H), 3.52 (d, J=18.2 Hz, 1H), 3.43-3.28 (m, 1H), 3.28-3.10 (m, 2H), 3.06-2.79 (m, 5H), 2.73-2.62 (m, 1H), 2.62-2.47 (m, 1H), 2.33-2.19 (m, 1H), 2.14-1.98 (m, 1H), 1.96-1.83 (m, 1H); LC/MS, m/z = 456.1 [M + H]⁺ (Calc: 455.6).

EXAMPLE 8

(6R,6aR,12aS)-2-hydroxy-15-methyl-9-(pyrrolidine-1-carbonyl)-6,6a,7,12-tetrahydro-5H-6,12a-(epiminoethano)naphtho[2,1-g]quinolin-10(11H)-one (12)
(6R,6aR,12aS)-2-hydroxy-N-((1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-15-methyl-10-oxo-6,6a,7,10,11,12-hexahydro-5H-6,12a-(epiminoethano)naphtho[2,1-g]quinoline-9-carboxamide (13)

(6*R*,6*aR*,12*aS*)-2-hydroxy-*N*-((1*S*,2*R*)-2-hydroxy-2,3-dihydro-1*H*-inden-yl)-15-methyl-10-oxo-6,6*a*,7,10,11,12-hexahydro-5*H*-6,12*a*-(epiminoethano)naphtho[2,1-*g*]quinoline-9-carboxamide (14)









(6*R*,6*aR*,12*aS*)-*N*-cyclohexyl-2-hydroxy-*N*,15-dimethyl-10-oxo-6,6*a*,7,10,11,12-hexahydro-5*H*-6,12*a*-(epiminoethano)naphtho[2,1-*g*]quinoline-9-carboxamide (15)

(6*R*,6*aR*,12*aS*)-2-hydroxy-9-(isoindoline-2-carbonyl)-15-methyl-6,6*a*,7,12-tetrahydro-5*H*-6,12*a*-(epiminoethano)naphtho[2,1-*g*]quinolin-10(11*H*)-one (16)

(6*R*,6*aR*,12*aS*)-2-hydroxy-9-((1*R*,3*R*,5*S*)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carbonyl)-15-methyl-6,6*a*,7,12-tetrahydro-5*H*-6,12*a*-(epiminoethano)naphtho[2,1-*g*]quinolin-10(11*H*)-one (17)

(6*R*,6*aR*,12*aS*)-9-(1,1-dioxidothiomorpholine-4-carbonyl)-2-hydroxy-15-methyl-6,6*a*,7,12-tetrahydro-5*H*-6,12*a*-(epiminoethano)naphtho[2,1-*g*]quinolin-10(11*H*)-one (18)

(6*R*,6*aS*,12*aR*)-11-ethyl-2,6*a*-dihydroxy-9-(isoindoline-2-carbonyl)-15-methyl-6,6*a*,7,12-tetrahydro-5*H*-6,12*a*-(epiminoethano)naphtho[2,1-*g*]quinolin-10(11*H*)-one (19)



The title compounds were prepared in a manner similar to that described in Example

7:

(a) **Compound 12:** ^1H NMR δ_{H} (400 MHz, D_2O): **mixture of salt diastereomers** 7.32 (s, 1H), 7.20-7.12 (m, 1H), 6.85 (d, $J=2.4$ Hz, 1H), 6.82-6.75 (m, 1H), 3.99-3.87 (m, 1H), 3.64-3.01 (m, 8H), 2.97 (s, 3H), 2.95-2.50 (m, 4H), 2.36-2.19 (m, 1H), 2.13-2.00 (m, 1H), 2.00-1.87 (m, 3H), 1.87-1.75 (m, 2H). LC/MS, $m/z = 420.1$ $[\text{M} + \text{H}]^+$ (Calc: 419.5).

5 (b) **Compound 13:** ^1H NMR δ_{H} (400 MHz, D_2O): 8.05 (s, 1H), 7.30-7.23 (m, 1H), 7.21-7.11 (m, 4H), 6.84 (d, $J=2.4$ Hz, 1H), 6.78 (dd, $J=8.4, 2.4$ Hz, 1H), 5.40 (d, $J=4.7$ Hz, 1H), 4.67 (t, $J=4.2$ Hz, 1H), 3.93-3.86 (m, 1H), 3.55 (d, $J=18.1$ Hz, 1H), 3.47-3.32 (m, 1H), 3.29-3.15 (m, 3H), 3.04-2.81 (m, 6H), 2.81-2.71 (m, 1H), 2.66-2.53 (m, 1H), 2.40-2.28 (m, 1H), 2.15-1.99 (m, 1H), 1.95-1.84 (m, 1H). LC/MS, $m/z = 498.1$ $[\text{M} + \text{H}]^+$ (Calc: 497.6).

10 (c) **Compound 14:** ^1H NMR δ_{H} (400 MHz, D_2O): 7.96 (s, 1H), 7.35-7.20 (m, 3H), 7.20-7.15 (m, 1H), 7.12 (d, $J=8.3$ Hz, 1H), 6.82 (d, $J=2.3$ Hz, 1H), 6.76 (dd, $J=8.3, 2.4$ Hz, 1H), 5.38 (d, $J=4.6$ Hz, 1H), 4.64 (t, $J=4.4$ Hz, 1H), 3.86-3.78 (m, 1H), 3.51 (d, $J=18.0$ Hz, 1H), 3.42-3.11 (m, 4H), 3.04-2.78 (m, 6H), 2.69-2.58 (m, 1H), 2.58-2.45 (m, 1H), 2.27-2.14 (m, 1H), 2.13-1.97 (m, 1H), 1.96-1.81 (m, 1H). LC/MS, $m/z = 498.1$ $[\text{M} + \text{H}]^+$ (Calc: 497.6).

15 (d) **Compound 15:** ^1H NMR δ_{H} (400 MHz, D_2O): **mixture of amide rotamers** 7.33-7.22 (m, 1H), 7.20-7.09 (m, 1H), 6.89-6.69 (m, 2H), 4.26-4.16 (m, 0.25H), 4.02-3.86 (m, 1H), 3.60-3.19 (m, 4.75H), 3.18-2.50 (m, 11H), 2.39-2.19 (m, 1H), 2.17-1.89 (m, 2H), 1.86-1.20 (m, 7.75H), 1.19-0.86 (m, 1H), 0.57-0.41 (m, 0.25H). LC/MS, $m/z = 462.3$ $[\text{M} + \text{H}]^+$ (Calc: 461.6).

20 (e) **Compound 16:** ^1H NMR δ_{H} (400 MHz, D_2O): 7.41 (s, 1H), 7.39-7.26 (m, 3H), 7.19-7.10 (m, 2H), 6.87 (d, $J=2.4$ Hz, 1H), 6.77 (dd, $J=8.4, 2.4$ Hz, 1H), 4.84 (s, 2H), 4.68-4.60 (m, 1H), 4.53-4.43 (m, 1H), 3.96-3.88 (m, 1H), 3.56 (d, $J=17.9$ Hz, 1H), 3.44-2.83 (m, 8H), 2.76-2.65 (m, 1H), 2.64-2.52 (m, 1H), 2.37-2.23 (m, 1H), 2.17-2.03 (m, 1H), 2.02-1.91 (m, 1H). LC/MS, $m/z = 468.1$ $[\text{M} + \text{H}]^+$ (Calc: 467.6).


25 (f) **Compound 17:** ^1H NMR δ_{H} (400 MHz, D_2O): 7.36 (d, $J=8.0$ Hz, 1H), 7.17 (d, $J=8.4$ Hz, 1H), 6.89-6.83 (m, 1H), 6.80 (dd, $J=8.4, 2.4$ Hz, 1H), 4.60-4.52 (m, 1H), 4.16-4.03 (m, 1H), 4.01-3.88 (m, 1H), 3.87-3.74 (m, 1H), 3.51 (d, $J=18.0$ Hz, 1H), 3.46-3.19 (m, 3H), 3.19-3.04 (m, 1H), 3.04-2.83 (m, 4H), 2.80-2.64 (m, 1H), 2.63-2.49 (m, 1H), 2.38-2.24 (m, 1H), 2.23-2.02 (m, 4H), 2.02-1.77 (m, 5H), 1.76-1.59 (m, 1H). LC/MS, $m/z = 476.2$ $[\text{M} + \text{H}]^+$ (Calc: 475.6).

(g) **Compound 18:** ^1H NMR δ_{H} (400 MHz, D_2O): 7.43 (s, 1H), 7.17 (d, $J=8.4$ Hz, 1H), 6.85 (d, $J=2.4$ Hz, 1H), 6.79 (dd, $J=8.3, 2.4$ Hz, 1H), 4.23-4.05 (m, 2H), 3.97-3.89 (m, 1H), 3.87-3.72 (m, 2H), 3.53 (d, $J=17.9$ Hz, 1H), 3.47-3.31 (m, 3H), 3.31-3.14 (m, 4H), 3.05-2.81 (m, 5H), 2.78-2.67 (m, 1H), 2.66-2.51 (m, 1H), 2.37-2.25 (m, 1H), 2.17-2.01 (m, 1H),
5 1.98-1.86 (m, 1H). LC/MS, $m/z = 484.2$ $[\text{M} + \text{H}]^+$ (Calc: 483.6).

(h) **Compound 19:** ^1H NMR δ_{H} (400 MHz, CD_3OD): 7.37-7.22 (m, 4H), 7.22-7.17 (m, 1H), 7.10 (d, $J=8.4$ Hz, 1H), 6.82 (d, $J=2.3$ Hz, 1H), 6.72 (dd, $J=8.3, 2.3$ Hz, 1H), 4.91-4.84 (m, 2H, overlap with water), 4.81-4.65 (m, 2H), 4.51-4.41 (m, 1H), 4.39-4.28 (m, 1H), 3.75-3.65 (m, 2H), 3.49-3.35 (m, 2H), 3.21-3.11 (m, 2H), 2.96 (s, 3H), 2.94-2.80 (m,
10 2H), 2.62 (d, $J=17.4$ Hz, 1H), 2.54 (td, $J=13.8, 5.0$ Hz, 1H), 1.71-1.63 (m, 1H), 1.49 (t, $J=7.1$ Hz, 3H). LC/MS, $m/z = 512.3$ $[\text{M} + \text{H}]^+$ (Calc: 511.6).

EXAMPLE 9

(6*R*,6*aS*,12*aR*)-15-(*tert*-butoxycarbonyl)-6*a*-hydroxy-2-methoxy-10-oxo-6,6*a*,7,10,11,12-hexahydro-5*H*-6,12*a*-(epiminoethano)naphtho[2,1-*g*]quinoline-9-carboxylic acid (**20**)
15




Into a flask containing a solution of **Compound 3** (0.040 g, 0.081 mmol) in THF (0.16 ml) was added a solution of NaOH (0.019 g, 0.483 mmol) in water (0.50 ml). The mixture was stirred on an oil bath at 33 °C for 3.5 h. The THF and MeOH were removed under reduced pressure and the pH of the remaining aqueous solution adjusted to 7.0 with 0.48 ml of 1N HCl. The resulting cloudy mixture was extracted with EtOAc. The EtOAc layer was washed twice with water and concentrated to dryness to give **Compound 20** as a pale yellow solid (0.016 g; yield 41%).
20

^1H NMR δ_{H} (400 MHz, CDCl_3): 13.78 (br. s., 1H), 12.42 (br. s., 1H), 8.20 (s, 1H), 7.06 (d, $J=8.36$ Hz, 1H), 6.64-6.81 (m, 2H), 4.60 (br. s., 1H), 3.88 (br. s., 1H), 3.70 (s, 3H), 3.42 (dd, $J=6.93, 18.65$ Hz, 1H), 3.17-3.33 (m, 2H), 2.99 (d, $J=18.71$ Hz, 1H), 2.60-2.83 (m, 4H), 2.18 (br. s., 1H), 1.50 (s, 9H), 1.34 (br. s., 1H); LC/MS, $m/z = 483$ $[\text{M} + \text{H}]^+$ (Calc: 482).
25

EXAMPLE 10

(6R,6aS,12aR)-11-ethyl-6a-hydroxy-2-methoxy-15-methyl-6,6a,7,12-tetrahydro-5H-6,12a-(epiminoethano)naphtho[2,1-g]quinolin-10(11H)-one (21)

5 (6R,6aS,12aR)-11-ethyl-2,6a-dihydroxy-15-methyl-6,6a,7,12-tetrahydro-5H-6,12a-(epiminoethano)naphtho[2,1-g]quinolin-10(11H)-one (22)



(a) To a suspension of **Compound 1** (9.68 g, 32.1 mmol, 1 eq) in Et₂O (125 mL) was added methyl formate (4.40 mL, 71.4 mmol, 2.2 eq) and NaOEt (7.22 g, 106 mmol, 3.3 eq). The reaction mixture was stirred at ambient temperature overnight then quenched with 100 mL saturated NH₄Cl solution. The resulting solid was isolated by filtration, washed twice with a minimum amount of water then once with Et₂O. The solid was dried under vacuum at 60 °C to give **Compound 1a** as a light tan powder that was used without further purification (7.814 g, 23.7 mmol, 74% yield). LC/MS, *m/z* = 330.2 [M + H]⁺ (Calc: 329).

(b) To a suspension of **Compound 1a** (19.58 g, 59.4 mmol, 1 eq) in acetonitrile (200 mL) was added methyl cyanoacetate (7.9 mL, 90 mmol, 1.5 eq) and piperidine (5.9 mL, 59.7 mmol, 1 eq). The reaction mixture was heated at 80 °C overnight. After cooling to

ambient temperature, the solids were isolated by filtration and washed with 25 mL acetonitrile to give **Compound 2** as a tan powder (16.658 g, 40.6 mmol, 68% yield). LC/MS, $m/z = 411.2$ $[M + H]^+$ (Calc: 410).

(c) To a mixture of **Compound 2** (10.07 g, 24.53 mmol, 1 eq) in argon-deoxygenated DMF (160 mL) was added K_2CO_3 (13.56 g, 98 mmol, 4 eq). Argon was bubbled through the reaction mixture for ~10 minutes followed by addition of the ethyl iodide (4.4 mL, 54.7 mmol, 2.2 eq). The vessel was sealed and stirred for 3 days. The solids were filtered off and rinsed with acetonitrile and the filtrate evaporated *in vacuo*. The residue was chromatographed over silica gel with 0-15% (10% NH_4OH in MeOH) in DCM. The product fractions were evaporated *in vacuo* and the residue triturated with 10 mL MeOH. The solids were isolated by filtration, washed twice with 3 mL MeOH and dried to give the product **Compound 7** as a yellow-tan powder (3.671 g, 8.37 mmol, 34%). LC/MS, $m/z = 439.0$ $[M + H]^+$ (Calc: 438).

(d) To a solution of **Compound 7** (3.671 g, 8.37 mmol, 1 eq) in 5:1 THF / Water (100 mL) was added $LiOH \cdot H_2O$ (0.420 g, 10 mmol, 1.2 eq). After stirring overnight the reaction was concentrated in vacuo to a moist solid. The solid was diluted with 50 mL water and 10 mL 1N HCl was added. Solid NaCl was added and the mixture extracted three times with 50 mL DCM. The organics were dried over $MgSO_4$, filtered and evaporated in vacuo to give **Compound 9** as a pale tan foam (2.91 g, 6.86 mmol, 82% yield). LC/MS, $m/z = 425.0$ $[M + H]^+$ (Calc: 424).

(e) To a solution of **Compound 9** (2.91 g, 6.86 mmol, 1 eq) in NMP (15 mL) was added Ag_2CO_3 (0.475 g, 1.72 mmol, 0.25 eq). Argon was bubbled through the reaction mixture for a couple minutes then the reaction was kept under nitrogen and heated at 140C for 6 days. The reaction mixture was evaporated *in vacuo* and the residue chromatographed over silica gel with 0-15% (10% NH_4OH in MeOH) in DCM. The product fractions were evaporated *in vacuo* and the residue triturated with a minimum amount of MeOH, filtered, rinsed once with a minimum amount of MeOH and dried under vacuum to give **Compound 21** as a tan powder (0.602 g, 1.58 mmol, 23% yield).

1H NMR δ_H (400 MHz, $DMSO-d_6$): 7.06 (d, $J=8.4$ Hz, 1H), 6.94 (d, $J=9.2$ Hz, 1H), 6.81 (d, $J=2.5$ Hz, 1H), 6.70 (dd, $J=8.4, 2.5$ Hz, 1H), 6.14 (d, $J=9.1$ Hz, 1H), 4.57 (br. s., 1H), 4.30-4.18 (m, 1H), 4.12-4.00 (m, 1H), 3.64 (s, 3H), 3.45 (d, $J=17.6$ Hz, 1H), 3.19-3.08 (m, 1H), 2.92-2.77 (m, 3H), 2.56-2.49 (m, 1H, overlap with DMSO), 2.42-2.34 (m, 1H), 2.33 (s,

3H), 2.26 (d, J=16.8 Hz, 1H), 2.17-2.05 (m, 1H), 2.04-1.92 (m, 1H), 1.32-1.21 (m, 4H); LC/MS, m/z = 381.1 $[M + H]^+$ (Calc: 380).

(f) To a solution of **Compound 21** (0.500 g, 1.31 mmol, 1 eq) in DCM (20 mL) was added 1M BBr₃ in DCM (4.0 mL, 4.0 mmol, 3 eq). After 2 hours, an additional amount of 1M BBr₃ in DCM (0.60 mL, 0.60 mmol, 0.5 eq) was added. After stirring overnight the reaction was quenched with 3.7 mL 5M NH₄OH in MeOH. The resulting liquid portion was decanted from the solids and chromatographed over silica gel with 0-16% (10% NH₄OH in MeOH) in DCM. The product fractions were evaporated *in vacuo* and the residue triturated with 3 mL MeOH, filtered, rinsed once with 1 mL MeOH and dried to give **Compound 22** as a pale tan powder (0.382 g, 1.04 mmol, 79% yield).

¹H NMR δ_H (400 MHz, DMSO-*d*₆): 9.10 (s, 1H), 6.98-6.90 (m, 2H), 6.63 (d, J=2.3 Hz, 1H), 6.52 (dd, J=8.2, 2.3 Hz, 1H), 6.14 (d, J=9.2 Hz, 1H), 4.54 (s, 1H), 4.24-4.14 (m, 1H), 4.13-4.02 (m, 1H), 3.33-3.25 (m, 1H, overlap with water), 3.14-3.04 (m, 1H), 2.91-2.73 (m, 3H), 2.57-2.50 (m, 1H, overlap with DMSO), 2.40-2.33 (m, 1H), 2.32 (s, 3H), 2.24 (d, J=16.8 Hz, 1H), 2.16-1.95 (m, 2H), 1.28 (t, J=7.0 Hz, 3H), 1.24-1.16 (m, 1H); LC/MS, m/z = 367.2 $[M + H]^+$ (Calc: 366).




EXAMPLE 11

The following Tables provide results on the efficacy of binding and activity response of exemplified Compounds of the Invention at the μ - and κ -opioid receptors.

In TABLE 1, binding affinity of certain Compounds of the Invention to the κ -opioid receptors was determined as described above.







In TABLE 2, activity response of certain Compounds of the Invention to the μ - and κ -opioid receptors was determined as described above for functional assays using HEK-293 cells.








TABLE 1
Binding Affinity of Certain Compounds of the Invention


Compd. No.	Structure	K_i (nM)			
		ORL-1	Opioid Receptor		
			μ	κ	δ
12		ND	ND	14.4 ± 2.81	ND
16		ND	ND	1.41 ± 0.52	ND
17		ND	ND	17.7 ± 7.60	ND

5 ND = not determined

TABLE 2
Activity Response of Certain Compounds of the Invention

Compd No.	Structure	Opioid Receptor			
		μ		κ	
		EC ₅₀ (nM)	E _{max} (%)	EC ₅₀ (nM)	E _{max} (%)
3		> 20 μ M	0.00	ND	ND
4		> 20 μ M	20.0 $\pm$ 2.08	ND	ND
6		2901 $\pm$ 867.6	23.0 $\pm$ 1.00	ND	ND
8		13346 $\pm$ 1797	40.7 $\pm$ 5.04	ND	ND
11		331.8 $\pm$ 61.7	32.3 $\pm$ 0.88	ND	ND
12		144.6 $\pm$ 27.9	35.3 $\pm$ 1.67	24.2 $\pm$ 11.9	9.50 $\pm$ 0.50

13		484.4± 113.5	34.0±3.21	ND	ND
14		432.0± 134.9	34.0±2.31	ND	ND
15		289.2±34.8	29.7±3.28	ND	ND
16		40.2±11.5	47.0±2.65	> 20 μM	0.00±1.53
17		239.9±36.8	27.5±2.53	151.9±28.8	9.74±1.51
18		462.5±88.4	33.2±3.30	ND	ND
19		288.0±49.6	30.8±2.31	ND	ND

20		> 20 μ M	3.00	ND	ND
----	---	--------------	------	----	----

ND = not determined

The *in vitro* test results of Tables 1 and 2 show that certain representative Compounds of the Invention generally have good binding affinity for κ -opioid receptors. It is believed that these compounds activate μ - and κ -opioid receptors as partial to full agonists. Compounds of the Invention are therefore expected to be useful to treat Conditions, particularly pain, that are responsive to the activation of one or more opioid receptors.


It will be understood by those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any embodiment thereof in view of the present disclosure.

Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

All patents, patent applications, and publications cited herein are fully incorporated by reference herein in their entirety.

WHAT IS CLAIMED IS:

1. A compound of Formula I:



or a pharmaceutically acceptable salt or solvate thereof, wherein:

R¹ is hydroxyl, cyano, carboxy, aminocarbonyl, alkyl or alkoxy, wherein each of said carboxy, aminocarbonyl, alkyl, and alkoxy is optionally substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxy, halo, haloalkyl, amino, alkylamino, dialkylamino, carboxy, alkoxy, alkoxycarbonyl, aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl, wherein said aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl are optionally substituted with 1, 2, or 3 independently selected R⁸ groups;

R² is selected from the group consisting of hydrogen, alkyl, and alkoxycarbonyl, wherein said alkoxycarbonyl is optionally substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxy, halo, haloalkyl, amino, alkylamino, dialkylamino, carboxy, alkoxy, alkoxycarbonyl, aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl, wherein said aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl are optionally substituted with 1, 2, or 3 independently selected R⁸ groups;

R³ is hydrogen, hydroxy, or halo; or alkoxy, alkylamino, or dialkylamino, any of which is optionally substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxy, halo, haloalkyl, amino, alkylamino, dialkylamino, carboxy, alkoxy, alkoxycarbonyl, aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl, wherein said aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl are optionally substituted with 1, 2, or 3 independently selected R⁸ groups;

R⁴ is hydrogen or alkyl;

Z is -C(=O)R⁵ or hydrogen, wherein

R⁵ is selected from the group consisting of

- a) OH;
- b) optionally substituted alkoxy; and


c) $-NR^6R^7$, wherein

R^6 is hydrogen or alkyl;


R^7 is hydrogen, alkyl, cycloalkyl, and arylalkyl, wherein two adjacent carbon atoms of said cycloalkyl ring are optionally fused to a phenyl ring; and wherein each of said cycloalkyl, alkyl, and arylalkyl is optionally substituted with 1, 2, or 3 independently selected R^8 groups; or R^6 and R^7 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring; and

Each R^8 is independently selected from the group consisting of hydroxy, halo, alkyl, haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, carboxy, alkoxy, and alkoxycarbonyl;

With the proviso that the compound is not any of




2. The compound of claim 1, having Formula II:




or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 , R^2 , R^3 , R^4 and Z are as defined in claim 1.

3. The compound of claim 1, having Formula **III**:




or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 , R^2 , R^3 , R^4 and Z are as defined in claim 1.

4. The compound of claim 1, having Formula **IV**:



or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 , R^2 , R^3 , R^4 and Z are as defined in claim 1.

5. The compound of claim 1, having Formula **V**:



or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 , R^2 , R^3 , R^4 and Z are as defined in claim 1.

6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 is hydroxyl or alkoxy, wherein said alkoxy is optionally substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxy, halo, haloalkyl, amino, alkylamino, dialkylamino, carboxy, alkoxy,

alkoxycarbonyl, aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl, wherein said aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl are optionally substituted with 1, 2, or 3 independently selected R⁸ groups.

7. The compound of claim 6, or a pharmaceutically acceptable salt or solvate thereof, wherein R¹ is hydroxyl or unsubstituted C₁₋₆ alkoxy.

8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt or solvate thereof, wherein R² is hydrogen.

9. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt or solvate thereof, wherein R² is alkyl.

10. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt or solvate thereof, wherein R² is alkoxycarbonyl optionally substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxyl, halo, haloalkyl, amino, alkylamino, dialkylamino, carboxy, alkoxy, alkoxycarbonyl, aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl, wherein said aryl, heteroaryl, heterocyclo, cycloalkyl, and cycloalkenyl are optionally substituted with 1, 2, or 3 independently selected R⁸ groups.

11. The compound of claim 10, or a pharmaceutically acceptable salt or solvate thereof, wherein R² is unsubstituted C₁₋₆ alkoxycarbonyl.


12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or solvate thereof, wherein R³ is hydrogen.

13. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or solvate thereof, wherein R³ is hydroxy.

14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt or solvate thereof, wherein R⁴ is hydrogen.


15. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt or solvate thereof, wherein Z is $-\text{C}(=\text{O})\text{R}^5$.
16. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof, wherein R^5 is OH.
17. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof, wherein R^5 is optionally substituted alkoxy.
18. The compound of claim 17, or a pharmaceutically acceptable salt or solvate thereof, wherein R^5 is unsubstituted C_{1-6} alkoxy.
19. The compound of claim 17, or a pharmaceutically acceptable salt or solvate thereof, wherein R^5 is C_{1-6} alkoxy substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxyl, halo, haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, carboxy, alkoxy, and alkoxycarbonyl.
20. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof, wherein
 R^5 is $-\text{NR}^6\text{R}^7$;
 R^6 is hydrogen or alkyl; and
 R^7 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and arylalkyl, wherein two adjacent carbon atoms of said cycloalkyl ring are optionally fused to a phenyl ring; and wherein each of said cycloalkyl, alkyl, and arylalkyl is optionally substituted with 1, 2, or 3 independently selected R^8 groups.
21. The compound of claim 20, or a pharmaceutically acceptable salt or solvate thereof, wherein R^7 is selected from the group consisting of C_{3-7} cycloalkyl and C_{6-14} aryl(C_{1-6})alkyl, wherein two adjacent carbon atoms of said C_{3-7} cycloalkyl ring are optionally fused to a phenyl ring; wherein said C_{3-7} cycloalkyl and C_{6-14} aryl(C_{1-6})alkyl are optionally substituted with 1, 2, or 3 optionally selected R^8 groups.

22. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof, wherein Z is selected from the group consisting of



23. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt or solvate thereof, wherein R^5 is $-NR^6R^7$ and R^6 and R^7 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring.

24. The compound of any one of claims 1-15 and 23, or a pharmaceutically acceptable salt or solvate thereof, wherein Z is selected from the group consisting of



25. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt or solvate thereof, wherein

R^1 is OH or unsubstituted C_{1-6} alkoxy;

R^2 is C_{1-4} alkyl or C_{1-6} alkoxy carbonyl, wherein said C_{1-6} alkoxy carbonyl is optionally substituted with 1, 2, or 3 substituents, each independently selected from the group consisting of hydroxy, halo, halo(C_{1-4})alkyl, amino, C_{1-4} alkylamino, di(C_{1-4})alkylamino, carboxy, C_{1-4} alkoxy, and C_{1-4} alkoxy carbonyl;


R^3 is hydrogen or hydroxy; and

R^4 is hydrogen or C_{1-4} alkyl.

26. The compound of any one of claims 1-14 and 25, or a pharmaceutically acceptable salt or solvate thereof, wherein Z is hydrogen.

27. The compound of claim 26, or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 is OH or unsubstituted C_{1-6} alkoxy; R^2 is C_{1-4} alkyl; R^3 is hydrogen or hydroxy; and R^4 is C_{1-4} alkyl.

28. The compound of claim 1, wherein said compound is a compound of Formula VI:




or a pharmaceutically acceptable salt or solvate thereof,
wherein


R^{10} is H or C_{1-6} alkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of hydroxy, halo, halo(C_{1-4})alkyl, amino, C_{1-4} alkylamino, di(C_{1-4})alkylamino, carboxy, C_{1-4} alkoxy, and C_{1-4} alkoxy carbonyl;

R^3 is hydrogen or OH;

and Z^1 is selected from the group consisting of




29. The compound of claim 1, selected from the group consisting of



or a pharmaceutically acceptable salt or solvate thereof.

30. The compound of claim 1, selected from the group consisting of



or a pharmaceutically acceptable salt or solvate thereof.

31. A pharmaceutical composition, comprising a therapeutically effective amount of the compound of any one of claims 1-30, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable carriers.

32. A method of treating or preventing a disorder responsive to the modulation of one or more opioid receptors in a patient, comprising administering to a patient in need of such treatment or prevention an effective amount of a compound of any one of claims 1-30, or a pharmaceutically acceptable salt or solvate thereof.

33. The method of claim 32, wherein the disorder is responsive to modulation of a μ -opioid receptor or κ -opioid receptor, or to modulation of both μ -opioid receptor and κ -opioid receptor.

34. The method of claim 33, wherein the disorder is responsive to modulation of the κ -opioid receptor.

35. The method of claim 32, wherein the disorder is pain.

36. A method of treating or preventing pain, constipation, diarrhea, pruritis, an addictive disorder, withdrawal from alcohol addiction or withdrawal from drug addiction in a patient, comprising administering an effective amount of a compound of any one of claims 1-30, or a pharmaceutically acceptable salt or solvate thereof, to the patient in need of such treatment or prevention.

37. The method of claim 36, wherein the method is for treating pain.

38. The method of claim 37, wherein said pain is acute pain, chronic pain or surgical pain.

39. The method of claim 38, wherein said pain is chronic pain.
40. The method of claim 39, wherein said chronic pain is neuropathic pain, postoperative pain, or inflammatory pain.
41. A method of modulating one or more opioid receptors in a patient, comprising administering to the patient an effective amount of a compound as claimed in any one of claims 1-30, or a pharmaceutically acceptable salt or solvate thereof.
42. The method of claim 41, wherein a μ - or κ -opioid receptor is modulated, or both μ - and κ -opioid receptors are modulated.
43. A compound as claimed in any one of claims 1- 30, or a pharmaceutically acceptable salt or solvate thereof, for use in treatment or prevention of a disorder responsive to the modulation of one or more opioid receptors in a patient.
44. The compound of claim 43, wherein the disorder is responsive to modulation of a μ -opioid receptor or κ -opioid receptor, or to modulation of both μ -opioid and κ -opioid receptors.
45. The compound for use according to claim 43 or 44, wherein the disorder is responsive to the modulation of the κ -opioid receptor.
46. The compound for use according to any one of claims 43-45, wherein the disorder is pain.
47. A compound as claimed in of any one of claims 1- 30, or a pharmaceutically acceptable salt or solvate thereof, for use in treatment or prevention of pain, constipation, diarrhea, pruritis, an addictive disorder, withdrawal from alcohol addiction or withdrawal from drug addiction in a patient.
48. The compound of claim 47, wherein said use is for the treatment or prevention of pain.

49. The compound of claim 48, wherein said pain is acute pain, chronic pain or surgical pain.

50. The compound of claim 49, wherein said chronic pain is neuropathic pain, postoperative pain, or inflammatory pain.

51. A compound as claimed in any one of claims 1- 30, or a pharmaceutically acceptable salt or solvate thereof, for use in modulating of one or more opioid receptors in a patient.

52. The compound as claimed in claim 51, wherein a μ - or κ -opioid receptor is modulated, or both μ - and κ -opioid receptors are modulated.

53. Use of a compound as claimed in any one of claims 1- 30, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treating or preventing a disorder responsive to the modulation of one or more opioid receptors.

54. The use of claim 53, wherein the disorder is responsive to modulation of μ -opioid receptor or κ -opioid receptor, or to a modulation of both μ -opioid receptor and κ -opioid receptor.

55. The use of claim 54, wherein the disorder is responsive to modulation of the κ -opioid receptor.

56. The use of any one of claims 53-55, wherein the disorder is pain.

57. Use of a compound as claimed in any one of claims 1-30, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treating or preventing pain, constipation, diarrhea, pruritis, an addictive disorder, withdrawal from alcohol addiction or withdrawal from drug addiction.

58. The use of claim 57, wherein said use is for treating or preventing pain.

59. The use of claim 58, wherein said pain is acute pain, chronic pain or surgical pain.

60. The use of claim 59, wherein said chronic pain is neuropathic pain, postoperative pain, or inflammatory pain.

61. Use of a compound as claimed in any one of claims 1-30, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for modulating of one or more opioid receptors.

62. The use as claimed in claim 61, wherein a μ - or κ -opioid receptor is modulated, or both μ - and κ -opioid receptors are modulated.

63. A compound as claimed in any one of claims 1-30, or a pharmaceutically acceptable salt or solvate thereof, for use as a medicament.

64. A compound as claimed in any one of claims 1-30, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is ^3H , ^{11}C , or ^{14}C radiolabeled.

65. A method of screening a candidate compound for the ability to bind to an opioid receptor using a radiolabeled compound of claim 64, comprising a) introducing a fixed concentration of the radiolabeled compound to the receptor to form a complex; b) titrating the complex with a candidate compound; and c) determining the binding of the candidate compound to said receptor.

66. A method of preparing a pharmaceutical composition, comprising admixing a therapeutically effective amount of a compound of any one of claims 1-30, or a pharmaceutically acceptable salt or solvate thereof, with a pharmaceutically acceptable carrier.

67. A kit, comprising a sterile container containing an effective amount of the compound of any one of claims 1-30, or a pharmaceutically acceptable salt, prodrug or solvate thereof, and instructions for therapeutic use.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2015/035606

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C07D 471/08 (2015.01)

CPC - C07D 471/08 (2015.05)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - A61K 31/437, 31/439, 31/485; C07D 471/08 (2015.01)

CPC - A61K 31/437, 31/439, 31/485; C07D 471/08 (2015.05) (keyword delimited)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC - 514/281; 546/43 (keyword delimited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Orbit, STN, Google Patents, PubChem, SureChEMBL, Google Scholar.

Search terms used: morphinan, heterocyclic morphinan, pyridone morphinan, +quinolin+, +naphtho+

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6,365,594 B1 (DONDIO et al) 02 April 2002 (02.04.2002) entire document	1-7, 28-30
A	US 7,655,671 B2 (SCHMIDHAMMER et al) 02 February 2010 (02.02.2010) entire document	1-7, 28-30
A	WO 91/05768 A1 (THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY UNITED STATES DEPARTMENT OF COMMERCE) 02 May 1991 (02.05.1991) entire document	1-7, 28-30
X, P	US 2014/0187549 A1 (PURDUE PHARMA LP) 03 July 2014 (03.07.2014) entire document	1-7, 28-30
A, T	WO 2015/102682 A1 (PURDUE PHARMA LP) 09 July 2015 (09.07.2015) entire document	1-7, 28-30

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

10 August 2015

Date of mailing of the international search report

01 SEP 2015

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Blaine Copenheaver

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2015/035606

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 8-27, 31-67
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.